Back to GetFilings.com




Use these links to rapidly review the document
UNITED SURGICAL PARTNERS INTERNATIONAL, INC. 2002 ANNUAL REPORT ON FORM 10-K TABLE OF CONTENTS



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended December 31, 2002

Commission file No. 000-32837

UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
(Exact name of Registrant as specified in its charter)

Delaware   75-2749762
(State of Incorporation)   (I.R.S. Employer
Identification No.)

15305 Dallas Parkway, Suite 1600

 

75001
Addison, Texas   (Zip Code)
(Address of principal executive offices)    

(972) 713-3500
(Registrant's telephone number, including area code)

Securities Registered Pursuant to Section 12(b) of the Act: None

Securities Registered Pursuant to Section 12(g) of the Act:

Title of each class

  Name of each exchange
on which registered

Common Stock, par value $.01 per share   The Nasdaq Stock Market
Rights to Purchase Series A Junior Participating Preferred Stock, par value $.01 per share   The Nasdaq Stock Market

        Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý    No o

        Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Parts I, II, III, and IV of this Form 10-K or any amendment to this Form 10-K. o

        Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2). Yes ý    No o

Aggregate market value of outstanding Common Stock held by non-affiliates of the Registrant, as of June 28, 2002   $ 581,718,183    
Number of shares of Common Stock outstanding as of March 20, 2003     27,166,860    

Documents Incorporated by Reference

        Part III—Portions of the registrant's definitive proxy statement to be filed pursuant to Regulation 14A for the Annual Meeting of Stockholders to be held May 22, 2003.





UNITED SURGICAL PARTNERS INTERNATIONAL, INC.

2002 ANNUAL REPORT ON FORM 10-K

TABLE OF CONTENTS

        

PART I        
    Item 1.   Business
    Item 2.   Properties
    Item 3.   Legal Proceedings
    Item 4.   Submission of Matters to a Vote of Security Holders

PART II

 

 

 

 
    Item 5.   Market for Registrant's Common Equity and Related Stockholder Matters
    Item 6.   Selected Consolidated Financial Data
    Item 7.   Management's Discussion and Analysis of Financial Condition and Results of Operations
    Item 7A.   Quantitative and Qualitative Disclosures about Market Risk
    Item 8.   Financial Statements and Supplementary Data
    Item 9.   Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

PART III

 

 

 

 
    Item 10.   Directors and Executive Officers of the Registrant
    Item 11.   Executive Compensation
    Item 12.   Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
    Item 13.   Certain Relationships and Related Transactions
    Item 14.   Controls and Procedures
    Item 15.   Exhibits, Financial Statement Schedules and Reports on Form 8-K

Note:

 

The responses to Items 10 through 13 will be included in the Company's definitive proxy statement to be filed pursuant to Regulation 14A for the Annual Meeting of Stockholders to be held May 22, 2003. The required information is incorporated into this Form 10-K by reference to that document and is not repeated herein.

2



FORWARD LOOKING STATEMENTS

        Certain statements contained in this Annual Report on Form 10-K, and the document incorporated herein by reference, including, without limitation, statements containing the words "believes", "anticipates", "expects", "continues", "will", "may", "should", "estimates", "intends", "plans" and similar expressions, and statements regarding the Company's business strategy and plans, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current expectations and involve known and unknown risks, uncertainties and other factors, many of which the Company is unable to predict or control, that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and regionally; foreign currency fluctuations; demographic changes; changes in, or the failure to comply with, laws and governmental regulations; the ability to enter into managed care provider arrangements on acceptable terms; changes in Medicare, Medicaid and other government funded payments or reimbursement in the U.S. and Western Europe; liability and other claims asserted against us; the highly competitive nature of healthcare; changes in business strategy or development plans of healthcare systems with which we partner; the ability to attract and retain qualified personnel, including physicians, nurses and other health care professionals; our significant indebtedness; the availability of suitable acquisition opportunities and the length of time it takes to accomplish acquisitions; our ability to integrate new businesses with our existing operations; the availability and terms of capital to fund the expansion of our business, including the acquisition and development of additional facilities and certain additional factors, risks and uncertainties discussed in this Annual Report on Form 10-K and the documents incorporated herein by reference. Given these uncertainties, investors and prospective investors are cautioned not to rely on such forward-looking statements. We disclaim any obligation and make no promise to update any such factors or forward-looking statements or to publicly announce the results of any revisions to any such factors or forward-looking statements, whether as a result of changes in underlying factors, to reflect new information as a result of the occurrence of events or developments or otherwise.


PART I

Item 1. Business

General

        United Surgical Partners International, Inc. (together with its subsidiaries, "we", the "Company" or "USPI") owns and operates short stay surgical facilities including surgery centers and private surgical hospitals in the United States, Spain and the United Kingdom. We focus on providing high quality surgical facilities that meet the needs of patients, physicians and payors better than hospital-based and other outpatient surgical facilities. We believe that our facilities (1) enhance the quality of care and the healthcare experience of patients, (2) offer significant administrative, clinical and economic benefits to physicians and (3) offer an efficient and low cost alternative to payors. We acquire and develop our facilities through the formation of strategic relationships with physicians and healthcare systems to better access and serve the communities in our markets. Our operating model is efficient, scalable and portable and we have adapted it to each of our national markets. We believe that our acquisition and development strategy and operating model enable us to continue to grow by taking advantage of highly-fragmented markets and an increasing demand for short stay surgery.

        Since physicians provide and influence the direction of healthcare worldwide, we have developed our operating model to encourage physicians to affiliate with us and to use our facilities. We operate our facilities, structure our strategic relationships and adopt staffing, scheduling and clinical systems and protocols with the goal of increasing physician productivity. We believe that our focus on physician

3



satisfaction, combined with providing high quality healthcare in a friendly and convenient environment for patients, will continue to increase the number of procedures performed at our facilities each year.

        Donald E. Steen, our chairman and chief executive officer, and Welsh, Carson, Anderson & Stowe formed USPI in February 1998. We operate surgery centers and private surgical hospitals in the United States and Western Europe. As of December 31, 2002, we operated 64 facilities, consisting of 54 in the United States, eight in Spain, and two in the United Kingdom. Of the 54 U.S. facilities, 26 are jointly owned with ten major not-for-profit healthcare systems. Overall, as of December 31, 2002, we held ownership interests in 61 of the facilities and operated the remaining three facilities, all in the United States, under management contracts. Our revenues for 2002 were $342.4 million, up 40% from $244.4 million for 2001.


Available Information

        We file proxy statements and annual, quarterly and current reports with the Securities and Exchange Commission. You may read and copy any document that we file at the SEC's public reference room located at 450 Fifth Street N.W., Washington, D.C. 20549. You may also call the Securities and Exchange Commission at 1-800-SEC-0330 for information on the operation of the public reference room. Our SEC filings are also available to you free of charge at the SEC's web site at http://www.sec.gov. We also maintain a website at http://www.unitedsurgical.com that includes links to our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to those reports. These reports are available on our website without charge as soon as reasonably practicable after such reports are filed with or furnished to the SEC.


Industry Background

        We believe many physicians prefer surgery centers and private surgical hospitals to general acute care hospitals. We believe that this is due to the elective nature of the procedures performed at our surgery centers and private surgical hospitals, which allows physicians to schedule their time more efficiently and therefore increase the number of surgeries they can perform in a given amount of time. In addition, these facilities usually provide physicians with greater scheduling flexibility, more consistent nurse staffing and faster turnaround time between cases. While surgery centers and private surgical hospitals generally perform scheduled surgeries, private acute care hospitals and national health service facilities generally provide a broad range of services, including high priority and emergency procedures. Medical emergencies often demand the unplanned use of operating rooms and result in the postponement or delay of scheduled surgeries, disrupting physicians' practices and inconveniencing patients. Surgery centers and private surgical hospitals in the United States, Spain and the United Kingdom are designed to improve physician work environments and improve physician efficiency. In addition, many physicians choose to perform surgery in facilities like ours because their patients prefer the comfort of a less institutional atmosphere and the convenience of simplified admissions and discharge procedures.

        According to SMG Marketing Group Inc.'s Freestanding Outpatient Surgery Center Directory, the number of outpatient surgery cases performed in freestanding surgery centers increased 169% from 2.6 million in 1991 to 7.0 million in 2001. Outpatient surgical procedures represented approximately 20% of all surgical procedures performed in the United States in 1981 compared to approximately 78% in 2001. New surgical techniques and technology, as well as advances in anesthesia, have significantly expanded the types of surgical procedures that are being performed in surgery centers and have helped drive the growth in outpatient surgery. Lasers, arthroscopy, enhanced endoscopic techniques and fiber optics have reduced the trauma and recovery time associated with many surgical procedures. Improved anesthesia has shortened recovery time by minimizing post-operative side effects such as nausea and

4


drowsiness, thereby avoiding the need for overnight hospitalization in many cases. In addition, some states in the United States now permit surgery centers to keep a patient for up to 23 hours. This allows more complex surgeries, previously only performed in an inpatient setting, to be performed in a surgery center.

        In addition to these technological and other clinical advancements, a changing payor environment has contributed to the rapid growth in outpatient surgery in recent years. Government programs, private insurance companies, managed care organizations and self-insured employers have implemented cost containment measures to limit increases in healthcare expenditures, including procedure reimbursement. These cost containment measures have greatly contributed to the significant shift in the delivery of healthcare services away from traditional inpatient hospitals to more cost-effective alternate sites, including surgery centers. We believe that surgery performed at a surgery center is generally less expensive than hospital-based outpatient surgery because of lower facility development costs, more efficient staffing and space utilization and a specialized operating environment focused on cost containment.

        Today, large healthcare systems in the United States generally offer both inpatient and outpatient surgery on site. In addition, a number of not-for-profit healthcare systems have begun to expand their portfolios of facilities and services by entering into strategic relationships with specialty operators of surgery centers. These strategic relationships enable not-for-profit healthcare systems to offer patients, physicians and payors the cost advantages, convenience and other benefits of outpatient surgery in a freestanding facility. Further, these relationships allow the not-for-profit healthcare systems to focus their attention and resources on their core business without the challenge of acquiring, developing and operating these facilities.

        Most countries in Western Europe provide their populations with some level of government-funded healthcare. Despite the success of these public programs, the practical limitations of these systems have resulted in delays or rationing of elective surgeries and certain other procedures. In many of these countries, funding and capacity constraints of public healthcare systems have created an opportunity for private healthcare systems to develop.

        While Spain's national health service covers substantially all of the country's population, a private healthcare industry has emerged that currently serves the 17% of Spain's population that maintains private insurance and another growing portion of the population that pays for elective procedures from personal funds. Total healthcare expenditures in Spain grew from 5.9% of gross domestic product, or GDP, in 1997 to 7.7% in 1999. In addition, Spain's GDP and wages have experienced compound annual growth of 3.4% and 2.7%, respectively, from 1996 to 2001. We believe that these increases support our view that the number of privately insured citizens, the amount of private healthcare expenditures and the resulting demand for private networks such as ours will continue to grow. We also believe that the growth in Spain's private healthcare industry has been driven in large part by an increase in the number of employers offering private insurance as a benefit to their employees. Like their U.S. counterparts, private insurance companies in Spain typically offer comprehensive health coverage. Since only 75 of the 355 private surgical hospitals in Spain are owned by multi-facility systems, we believe an opportunity exists to expand our private hospital network that will enable us to negotiate more effectively with the country's large health insurance companies. Our facilities also supplement the national health service as public hospitals periodically refer overload cases to our facilities.

        We are able to accept or reject these cases based on the available capacity of our facilities and the profitability of the cases. For the year ended December 31, 2002, we derived approximately 71% of our revenues in Spain from private insurance, approximately 18% from private pay and approximately 11% from government payors.

5


        The United Kingdom also provides government-funded healthcare to all of its residents through a national health service. It, however, is also subject to funding and capacity limitations. Since the demand for healthcare services exceeds the public system's capacity, U.K. residents may encounter waiting lists for elective surgery of up to 18 months as well as delays in obtaining cancer biopsies and other diagnostic procedures. The World Health Organization reports that 25,000 people die unnecessarily of cancer in Britain each year due to underfinanced and poorly managed cancer programs. In response to these shortfalls, private healthcare networks and private insurance companies have developed in the United Kingdom. Approximately 11% of the U.K. population has private insurance to cover elective surgical procedures, and another rapidly growing segment of the population pays for elective procedures from personal funds. For the year ended December 31, 2002, in the United Kingdom, we derived approximately 60% of our revenues from private insurance, approximately 33% from private pay patients and approximately 7% from government payors.


Our Business Strategy

        Our goal is to steadily increase our revenues and cash flows by becoming a leading operator of surgery centers and private surgical hospitals in the United States and selected nations in Western Europe. The key elements of our business strategy are to:

        Since physicians provide and influence the direction of healthcare worldwide, we have developed our operating model to encourage physicians to affiliate with us and to use our facilities as an extension of their practices. We believe we attract physicians because we design our facilities, structure our strategic relationships and adopt staffing, scheduling and clinical systems and protocols to increase physician productivity and promote their professional and financial success. We believe this focus on physicians, combined with providing high quality healthcare in a friendly and convenient environment for patients, will continue to increase case volumes at our facilities. In addition, in the United States, we generally offer physicians the opportunity to purchase equity interests in the facilities they use as an extension of the physicians' practices. We believe this opportunity attracts quality physicians to our facilities and ownership increases the physicians' involvement in facility operations, enhancing quality of patient care, increasing productivity and reducing costs.

        Through strategic relationships with us, healthcare systems can benefit from our operating expertise and create a new cash flow opportunity with limited capital expenditures. We believe that these relationships also allow not-for-profit healthcare systems in particular to attract and retain physicians and improve their hospital operations by focusing on their core business. We also believe that strategic relationships with these healthcare systems help us to develop more quickly, relationships with physicians, communities, suppliers and payors. Generally, the healthcare systems with which we develop relationships have strong local market positions and excellent reputations that we use in branding our facilities. In addition, our relationships with healthcare systems enhance our acquisition and development efforts by (1) providing opportunities to acquire facilities the systems may own, (2) providing access to physicians already affiliated with the systems, (3) attracting additional physicians

6


to affiliate with newly developed facilities, and (4) encouraging physicians who own facilities to consider a strategic relationship with us.

        Our primary strategy is to grow selectively in markets in which we already operate facilities. We believe that selective acquisitions and development of new facilities in existing markets allow us to leverage our existing knowledge of these markets and to improve operating efficiencies. In particular, our experience has been that newly developed facilities in markets where we already have a presence and a not-for-profit hospital partner are the best use of the company's invested capital.

        We may continue to enter targeted markets by acquiring and developing surgical facilities. In the United States, we expect to do this primarily in conjunction with a local healthcare system or hospital. We typically target the acquisition or development of multi-specialty centers that perform high volume, non-emergency, lower risk procedures requiring lower capital and operating costs than hospitals. In addition, we will also consider the acquisition of multi-facility companies.

        In determining whether to enter a new market, we examine numerous criteria, including:

        Upon identifying a target facility, we conduct financial, legal, engineering, operational, technology and systems audits of the facility and conduct interviews with the facility's management, affiliated physicians and staff. Once we acquire or develop a facility, we focus on upgrading systems and protocols, including implementing our proprietary methodology of defined processes and information systems, to increase case volume and improve operating efficiencies.

        Once we acquire a new facility, we integrate it into our existing network by implementing a specific action plan to support the local management team and incorporate the new facility into our group purchasing contracts. We also implement our systems and protocols to improve operating efficiencies and contain costs. Our most important operational tool is our management system "Every Day Giving Excellence," which we refer to as USPI's EDGE. This proprietary measurement system allows us to track our clinical, service and financial performance, best practices and key indicators in each of our facilities. Our goal is to use USPI's EDGE to ensure that we provide each of the patients using our facilities with high quality healthcare, offer physicians a superior work environment and eliminate inefficiencies. Using USPI's EDGE, we track and monitor our performance in clinical care areas such as (1) providing surgeons the equipment, supplies and surgical support they need, (2) starting cases on

7


time, (3) minimizing turnover time between cases, and (4) providing efficient schedules. USPI's EDGE compiles and organizes the specified information on a daily basis and is easily accessed over the Internet by our facilities on a secure basis. The information provided by USPI's EDGE enables our employees, facility administrators and management to analyze trends over time and share processes and best practices among our facilities. In addition, the information is used as an evaluative tool by our administrators and as a budgeting and planning tool by our management. USPI's EDGE is now deployed in over 94% of our U.S. facilities.


Operations

        Our operations in the United States consist primarily of our ownership and management of surgery centers. We have ownership interests in 48 surgery centers and three private surgical hospitals and manage or operate, through consulting agreements, three additional surgery centers. Additionally, we own interests in and will operate one surgery center and one private surgical hospital that are currently under construction. We also intend to develop two additional surgery centers which we anticipate will open in the second half of 2003, and we have various other potential projects in the early stages of development, some of which may begin construction during 2003. Over 2,000 physicians have access privileges to use our facilities. Our surgery centers are licensed outpatient surgery centers and are generally equipped and staffed for multiple surgical specialties and located in freestanding buildings or medical office buildings. Our average surgery center has approximately 13,000 square feet of space with four or five operating rooms, as well as ancillary areas for preparation, recovery, reception and administration. Our surgery center facilities range from a 4,000 square foot, two operating room facility to a 20,000 square foot, six operating room facility. Our surgery centers are normally open weekdays from 7:00 a.m. to approximately 5:00 p.m. or until the last patient is discharged. We estimate that a surgery center with four operating rooms can accommodate up to 6,000 procedures per year.

        Our surgery center support staff typically consists of registered nurses, operating room technicians, an administrator who supervises the day-to-day activities of the surgery center, a receptionist and a small number of office staff. Each center also has a medical director, who is typically an anesthesiologist and responsible for and supervises the quality of medical care provided at the center. Use of our surgery centers is limited to licensed physicians, podiatrists and oral surgeons who are also on the medical staff of a local accredited hospital. Each center maintains a peer review committee consisting of physicians who use our facilities and who review the professional credentials of physicians applying for surgical privileges.

        All of our surgery centers eligible for accreditation are accredited by the Joint Commission on Accreditation of Healthcare Organizations or by the Accreditation Association for Ambulatory Healthcare. We believe that accreditation is the quality benchmark for managed care organizations. Many managed care organizations will not contract with a facility until it is accredited. We believe that our historical performance in the accreditation process reflects our commitment to providing high quality care in our surgery centers.

        Generally, our surgery centers are limited partnerships, limited liability partnerships or limited liability companies in which ownership interests are also held by local physicians who are on the medical staff of the centers. Our ownership interests in the centers range from 10% to 100%. Our partnership and limited liability company agreements typically provide for the quarterly pro rata distribution of cash equal to net revenues from operations, less amounts held in reserve for expenses and working capital. We also have a management agreement with each of the centers under which we provide day-to-day management services for a management fee that is typically a percentage of the net revenues of the center.

8



        Our partnership and limited liability company agreements typically provide that if various regulatory changes take place we will be obligated to purchase some or all of the ownership interests of the physicians in the partnerships or limited liability companies that own and operate the applicable surgery centers. The regulatory changes that could trigger such an obligation include changes that:

        Typically, our partnership and limited liability company agreements allow us to use shares of our common stock as consideration for the purchase of a physician's interest should we be required to purchase these interests. In the event we are required to purchase these interests and our common stock does not maintain a sufficient valuation, we may be required to use cash for the acquisition of a physician's interest. As a result, the triggering of these obligations and the possible termination of our affiliation with these physicians, which we do not believe is likely, could have a material adverse effect on us.

        Our business depends upon the efforts and success of the physicians who provide medical services at our facilities and the strength of our relationships with these physicians. Our business could be adversely affected by the loss of our relationship with, or a reduction in use of our facilities by, a key physician or group of physicians. The physicians that affiliate with us and use our facilities are not our employees. However, we generally offer the physicians the opportunity to purchase equity interests in the facilities they use.

        A key element of our business strategy is to pursue strategic relationships with not-for-profit healthcare systems in selected markets. Twenty-six of our facilities are jointly-owned with ten not-for-profit healthcare systems. As of December 31, 2002, we had joint ventures with six established not-for-profit healthcare systems in the United States: the Baylor Health Care System in Dallas, Texas; Meridian Health System in Northern New Jersey; Saint Thomas Health Services in Middle Tennessee; Memorial Hermann Healthcare System in Houston, Texas; Northside Hospital in Atlanta, Georgia; and Robert Wood Johnson University Hospital in East Brunswick, New Jersey. These joint ventures own interests in an aggregate of 22 of our facilities. In addition to the facilities owned by these joint ventures, four of our other facilities are co-owned with four additional not-for-profit healthcare systems. Additionally, we entered into a joint venture agreement in March 2003 with St. Joseph's Hospital and Medical Center in Phoenix, Arizona. This joint venture does not yet operate any facilities. We hope to develop these relationships into future opportunities for multi-facility strategic relationships. We intend to structure our future joint ventures with service providers in a manner similar to our joint venture with Baylor.

        Our largest strategic relationship is with Baylor. The Baylor joint ventures own interests in limited liability companies, limited liability partnerships and limited partnerships which own and operate surgery centers. Our alliance agreements with Baylor do not have expiration dates but may be terminated with the mutual consent of both parties, if the joint ventures are determined to be illegal due to a change in laws or regulations or upon stated changes in control of our company. In addition, agreements governing the joint ventures have provisions governing management power, dissolution events and veto power. These joint ventures own an outpatient surgery network that serves the approximately four million persons located in the Dallas/Fort Worth area. The Baylor joint ventures

9



currently have ownership interests in thirteen operational surgery centers and one surgical hospital. We also have a joint venture with the Meridian Health System in Wall, New Jersey. This joint venture currently operates two surgery centers. In addition, in August 2001 we entered into a joint venture with Saint Thomas Health Services in Nashville, Tennessee. We operate three surgery centers in joint ownership with Saint Thomas and expect to contribute one additional surgery center to the joint venture. In addition, we entered into a joint venture with Memorial Hermann Healthcare System in March 2002 to develop a surgical hospital in Houston, Texas which opened in December 2002. Our joint venture with Northside Hospital currently operates one surgery center in Atlanta, Georgia. In June 2002 we entered into a joint venture with Robert Wood Johnson University Hospital. This joint venture currently operates one surgery center in East Brunswick, New Jersey. All of our joint ventures require both parties to provide the other party the opportunity to participate in any surgery center project within specified geographic regions prior to the other party participating in the project.

        We believe our operations in Spain comprise one of the largest private hospital networks in this highly fragmented market. We own and operate eight private surgical hospitals (including one that we acquired subsequent to December 31, 2002), one surgery center and a diagnostic facility in Spain and over 700 physicians use our facilities. These facilities, located primarily in Barcelona, Madrid and Seville, range in size from 19 beds to 134 beds with an average of 97 beds. In this market, we focus primarily on five specialties: obstetrics/gynecology; orthopedic surgery; general surgery; internal medicine; and plastic surgery.

        In addition, we are developing our brand name, "USPE," in all of our markets in Spain in an effort to attract top quality physicians and a greater number of patients. We are developing this brand by leveraging the reputation of our more prominent physicians and facilities, particularly Instituto Universitario Dexeus in Barcelona. Dexeus is one of only two private teaching hospitals in Spain. We believe Dexeus' affiliation with the University of Barcelona, which has nationally renowned physicians, makes it one of Spain's most respected private hospitals and greatly enhances the USPE brand image. To this end, we also intend to develop our brand name through future acquisitions of private surgical hospitals.

        We acquired Parkside Hospital in Wimbledon, a suburb southwest of London, and Holly House Hospital in a suburb northeast of London near Essex in April 2000. Parkside has 69 registered acute care beds, including four high dependency beds, on three floors. The hospital has four operating theatres, including a dedicated endoscopy suite. Parkside also has its own on site pathology laboratory, pharmacy and diagnostic suite with an MRI scanner, CT scanner, two X-ray screening rooms and a color Doppler ultrasound machine. Approximately 270 surgeons and physicians, all of whom hold or have held consulting positions in hospitals operated by the United Kingdom's national health service, have admitting privileges to the hospital. Parkside has established practices including orthopedics, gynecology and general surgery, as well as neurosurgery and endoscopic procedures.

        We are in the process of developing a comprehensive cancer treatment center, the Parkside Clinic, near Parkside Hospital. Our development of Parkside Clinic has the support of a number of oncologists at Parkside Hospital and the center has already contracted with the BUPA Group, Britain's largest insurance company. We anticipate that the center will provide superior inpatient and outpatient services. We also anticipate that Parkside Clinic will be fully operational in 2003 and will provide radiotherapy, chemotherapy and nuclear medicine facilities on an outpatient basis with inpatient cancer services being provided at Parkside Hospital. Parkside Clinic also will provide additional space for expansion of other specialties and programs at Parkside Hospital.

10



        Holly House Hospital has been an acute care hospital for 20 years and has 59 registered acute care beds on two floors, including three high dependency beds. The hospital has three operating theatres and its own on site pathology laboratory and pharmacy with cytotoxic reconstitution facilities to serve its expanding oncology program. A diagnostic suite houses MRI and CT scanners and two X-ray screening rooms together with a color Doppler ultrasound machine. Over 100 surgeons and physicians have admitting privileges at the hospital. The hospital has established orthopedic and general surgery practices and is developing oncology and plastic surgery programs.

        The following table sets forth the percentage of our revenues determined based on internally reported case volume from our U.S. facilities and internally reported revenue from our Spain and U.K. facilities for the year ended December 31, 2002 from each of the following specialties:

Specialty

  Total
  U.S.
  Spain
  U.K.
 
Orthopedic   26 % 26 % 20 % 37 %
Pain management   14   24     1  
Obstetrics/gynecology   10   4 (1) 19 (2) 15 (3)
General surgery   8   5   12   18  
Ear, nose and throat   4   5   3   4  
Gastrointestinal   10   12   8   2  
Plastic surgery   5   5   4   7  
Ophthalmology   7   9   3   5  
Other   16   10   31   11  
   
 
 
 
 
  Total   100 % 100 % 100 % 100 %
   
 
 
 
 

(1)
Includes gynecology only.

(2)
Includes obstetrics and gynecology.

(3)
Includes gynecology and in vitro fertilization.

        The following table sets forth the percentage of our revenues determined based on internally reported case volume from our U.S. surgical facilities and internally reported revenue from our Spain and U.K. facilities for the year ended December 31, 2002 from each of the following payors:

Payor

  Total
  U.S.
  Spain
  U.K.
 
Private insurance   68 % 69 % 71 % 60 %
Self-pay   11   3   18   33  
Government   18   23 (1) 11   7  
Other   3   5      
   
 
 
 
 
  Total   100 % 100 % 100 % 100 %
   
 
 
 
 

(1)
Based solely on case volume. Because government payors typically pay less than private insurance, the percentage of our U.S. revenue attributable to government payors is approximately 10% for Medicare and 1% for Medicaid.

11


        The following table sets forth information relating to the not-for-profit healthcare systems with which we are affiliated as of December 31, 2002:

Healthcare System

  Geographical Focus
  Number of
Facilities
Operated

Baylor Healthcare System   Dallas/Ft. Worth, Texas   14
Saint Thomas Health Services   Middle Tennessee   3
Meridian Health System   Northern New Jersey   2
Decatur General Hospital   Decatur, Alabama   1
Northside Hospital   Atlanta, Georgia   1
St. Rose Dominican Hospital   Las Vegas, Nevada   1
Robert Wood Johnson University Hospital   East Brunswick, New Jersey   1
Johnson City Medical Center   Johnson City, Tennessee   1
Covenant Healthcare   Knoxville, Tennessee   1
Memorial Hermann Healthcare System   Houston, Texas   1

        Additionally, we entered into a joint venture agreement in March 2003 with St. Joseph's Hospital and Medical Center in Phoenix, Arizona. This joint venture does not yet operate any facilities.

Facilities

        The following table sets forth information relating to the surgery centers that we operate as of December 31, 2002:

Facility

  Date of
Acquisition
or
Affiliation

  Number
of
Operating
Rooms

  Percentage
Owned by
USPI

 
United States              
*Decatur Surgery Center, Decatur, Alabama(1)   7/29/98   3   61 %
Warner Park Surgery Center, Chandler, Arizona(1)   7/1/99   4   80  
Coast Surgery Center of South Bay, Inc., Torrance, California   12/18/01   3   63  
San Gabriel Valley Surgical Center, West Covina, California   11/16/01   4   80  
Destin Surgery Center, Destin, Florida   9/25/02   3   30  
University Surgical Center, Winter Park, Florida   10/15/98   3   70  
Surgery Center of Sarasota, Sarasota, Florida   10/12/01   4   66  
East West Surgery Center, Austell, Georgia   9/1/00 (4) 3   82  
*Advanced Surgery Center, Canton, Georgia(1)   3/27/02   3   50  
Northwest Georgia Orthopaedic Surgery Center, Marietta, Georgia   11/1/00 (4) 2   15  
Lawrenceville Surgical Center, Lawrenceville, Georgia   8/1/01   2   15  
Resurgens Surgery Center, Atlanta, Georgia   10/1/98 (4) 4   40  
Roswell Surgery Center, Roswell, Georgia   10/1/00 (4) 2   15  
Creekwood Surgery Center, Kansas City, Missouri(1)   7/29/98   3   66  
*Parkway Surgery Center, Henderson, Nevada   8/3/98   5   47  
*Robert Wood Johnson Surgery Center, East Brunswick, New Jersey   6/26/02   5   50  
*Shrewsbury Ambulatory Surgery Center, Shrewsbury, New Jersey   4/1/99   4   25  
*Toms River Surgery Center, Toms River, New Jersey   3/15/02   4   40  
New Mexico Orthopaedic Surgery Center, Albuquerque, New Mexico   2/29/00 (4) 4   51  
Las Cruces Surgery Center, Las Cruces, New Mexico(1)   2/1/01   3   50  
Day-Op Center of Long Island, Mineola, New York(2)   12/4/98   4   0  
Austintown Ambulatory Surgery Center, Austintown, Ohio (1)   4/12/02   5   20  
Eastside Surgery Center, Columbus, Ohio (3)   3/20/00 (4) 4   0  
Riverside Outpatient Surgery Center, Columbus, Ohio (3)   3/20/00 (4) 6   0  
Surgery Center in Middleburg Heights, Middleburg Heights, Ohio (1)   6/19/02   6   62  
Zeeba Surgery Center, Lyndhurst, Ohio(1)   10/11/02   5   80  
Oklahoma City North Ambulatory Surgery Center, Oklahoma City, Oklahoma(1)   3/27/02   4   51  
*Mountain Empire Surgery Center, Johnson City, Tennessee   2/2/00 (4) 4   20  

12


*Baptist Ambulatory Surgery Center, Nashville, Tennessee   3/1/98 (4) 6   20  
*Middle Tennessee Ambulatory Surgery Center, Murfreesboro, Tennessee   7/29/98   4   42  
*Parkwest Surgery Center, Knoxville, Tennessee   7/26/01   5   22  
*Saint Thomas Campus SurgiCare, Nashville, Tennessee   7/15/02   5   25  
Physicians Pavilion Surgery Center, Nashville, Tennessee (1)   7/29/98   4   75  
*Arlington Surgery Center, Arlington, Texas (1)   2/1/99   3   44  
*Baylor Surgicare, Dallas, Texas (1)   6/1/99   6   25  
*Bellaire Surgery Center, Fort Worth, Texas   10/15/02   4   22  
*Denton Surgicare, Denton, Texas (1)   2/1/99   4   21  
Doctors Surgery Center (Houston), Pasadena, Texas (1)   9/1/99   4   78  
*Lewisville SurgiCare Partners, Lewisville, Texas (1)(3)   9/16/02   3   0  
*Medical Centre Surgicare, Fort Worth, Texas (1)   12/18/98   6   46  
*Metroplex Surgery Center, Bedford, Texas (1)   12/18/98   5   45  
Corpus Christi Outpatient Surgery, Corpus Christi, Texas (1)   5/1/02   5   69  
*North Texas Surgery Center, Dallas, Texas (1)   12/18/98   4   44  
*Physicians Day Surgery Center, Dallas, Texas   10/12/00   4   25  
*Premier Ambulatory Surgery Center of Garland, Garland, Texas   2/1/99   3   46  
*Grapevine Surgery Center, Grapevine, Texas   2/6/02   3   11  
*Texas Surgery Center, Dallas, Texas(1)   6/1/99   4   25  
United Surgery Center—Southeast, Houston, Texas(1)   9/1/99   3   94  
*Valley View Surgery Center, Dallas, Texas(1)   12/18/98   4   56  
Surgi-Center of Central Virginia, Fredericksburg, Virginia   11/29/01   4   83  
Teton Outpatient Services, Jackson Hole, Wyoming   8/1/98 (4) 2   56  

Spain

 

 

 

 

 

 

 
Centro de Cirugia Ambulatario, Barcelona   3/1/99   3   100  
USP Dermoéstetica, S.L. Madrid   5/1/99   2   70  

*
Facilities jointly owned with not-for-profit hospital systems.
(1)
Licensed and equipped to accommodate 23-hour stays.
(2)
Operated through a consulting and administrative agreement.
(3)
Management agreement only.
(4)
Indicates date of acquisition by OrthoLink. We acquired OrthoLink in February 2001.

        The following table sets forth information relating to the private surgical hospitals that we operate as of December 31, 2002:

Facility

  Date of
Acquisition
or
Affiliation

  Number of
Operating
Rooms

  Number of
Beds

  Percentage
Owned by
USPI

 
United States                  
*Frisco Surgical Hospital, Frisco, Texas   9/30/02   6   13   20 %
*Sugar Land Surgical Hospital, Sugar Land, Texas   12/28/02   4   6   32  
TOPS Specialty Hospital, Houston, Texas   7/1/99   7   12   53  

Spain

 

 

 

 

 

 

 

 

 
Instituto Universitario Dexeus, Barcelona   4/30/98   12   106   79  
Hospital Santa Teresa, La Coruña   11/5/98   5   133   96  
Hospital Sagrado Corazón, Seville   10/16/98   9   95   100  
Clinica Nuestra Señora de la Esperanza, Vitoria   10/5/98   3   19   100  
Clinica San Camilo, Madrid   3/15/00   8   130   93  
Clinica San Jose, Madrid   11/1/00   7   72   100  
Juan XXIII, Madrid (1)   2/1/00       100  
Hospital San Carlos, Murcia   2/1/02   6   134   100  

United Kingdom

 

 

 

 

 

 

 

 

 
Parkside Hospital, Wimbledon   4/6/00   4   69   100  
Holly House Hospital, Essex   4/6/00   3   59   100  

*
Facilities jointly owned with not-for-profit hospital systems.

13


(1)
Imaging center only.

        In addition, the Company operates the following facilities under short-term management contracts which expire at various dates through 2006: Southwest Ambulatory Surgery Center, L.L.C., which is a surgery center located in Oklahoma City, Oklahoma; The Ambulatory Surgery Center of Tyler, Ltd., which is a surgery center located in Tyler, Texas; and Oklahoma Center for Orthopedic and Multi-Specialty Surgery, which is a surgical hospital located in Oklahoma City, Oklahoma. The Company holds no ownership in these facilities.

        We lease the majority of the facilities where our various surgery centers and private surgical hospitals conduct their operations. Our leases have initial terms ranging from one to twenty years and most of the leases contain options to extend the lease period for up to ten additional years.

        Our corporate headquarters is located in Dallas, Texas. We currently lease approximately 40,000 square feet of space at 15305 Dallas Parkway, Addison, Texas. This lease will expire in April 2011.

        Our office in the United Kingdom is located in London. We currently lease 1,900 square feet. The lease expires in February 2004.

        Our Spanish offices are located in Madrid and Barcelona. We currently lease 2,800 square feet of space in Madrid. The lease expires in December 2003. Additionally, we lease 3,100 square feet of space in Barcelona. The lease expires in December 2007.

        We also lease 10,400 square feet of space in Brentwood, Tennessee, which was the former OrthoLink headquarters and currently serves as a regional office. The lease expires in November 2008.


Development

        The following table sets forth information relating to facilities that are currently under construction:

Facility Location

  Type
  Expected
Opening
Date

  Number of Operating
Rooms/Beds

Cottonwood, Arizona   Surgery Center   4Q 2003   2 ORs
Chandler, Arizona   Surgical Hospital   3Q 2003   4 ORs/16 beds

        We also intend to develop surgery centers in Atlanta, Georgia and Nashville, Tennessee which we anticipate will open in the second half of 2003. We are in various stages of negotiation with various entities regarding possible joint venture, development or acquisition projects. In the United Kingdom, our Parkside Hospital is in the process of developing a cancer treatment center. Any acquisition or development in these or other markets must meet our acquisition and development criteria. We cannot assure you that we will be successful in developing or acquiring facilities in any of these markets.


Marketing

        Our sales and marketing efforts are directed primarily at physicians, which are principally responsible for referring patients to our facilities. We market our facilities to physicians by emphasizing (1) the high level of patient satisfaction with our surgery centers, which is based on patient surveys we take concerning our facilities, (2) the quality and responsiveness of our services, and (3) the practice efficiencies provided by our facilities. In those U.S. markets in which we have established a strategic alliance with a not-for-profit healthcare system, we coordinate the marketing effort with the healthcare system and generally benefit from this managed care strategy. We also directly negotiate agreements with third-party payors, which generally focus on the pricing, number of facilities in the market and affiliation with physician groups in a particular market. Maintaining access to physicians and patients through third-party payor contracting is essential for the economic viability of most of our facilities.

14




Competition

        In all of our markets, we compete with other providers, including major acute care hospitals. Hospitals have various competitive advantages over us, including their established managed care contracts, community position, physician loyalty and geographical convenience for physicians' in-patient and out-patient practices. However, we believe that, in comparison to hospitals with which we compete for managed care contracts, our surgery centers and private surgical hospitals compete favorably on the basis of cost, quality, efficiency and responsiveness to physician needs in a more comfortable environment for the patient.

        We compete with other providers in each of our markets for patients and for contracts with insurers or managed care payors. Competition for managed care contracts with other providers is focused on the pricing, number of facilities in the market and affiliation with key physician groups in a particular market. We also encounter competition with other companies for acquisition and development of facilities and in the United States for strategic relationships with not-for-profit healthcare systems and physicians.

        There are several large, publicly-held companies, or divisions or subsidiaries of large publicly-held companies, that acquire and develop freestanding multi-specialty surgery centers and private surgical hospitals. Some of these competitors have greater resources than we do. The principal competitive factors that affect our ability and the ability of our competitors to acquire surgery centers and private surgical hospitals are price, experience and reputation and access to capital. Further, in the United States some physician groups develop surgery centers without a corporate partner. It is generally difficult, however, for a single practice to create effectively the efficient operations and marketing programs necessary to compete with other provider networks and companies. As a result, and also due to the financial investment necessary to develop surgery centers and private surgical hospitals, many healthcare systems and physician groups are attracted to corporate partners such as us.

        In the United Kingdom, we face competition from both the national health service and other privately operated hospitals, including hospitals owned by the BUPA Group, our primary competitor in the United Kingdom. Across the United Kingdom, a large number of private hospitals are owned by the four largest hospital operators. In addition, the two largest payors account for over half of the privately insured market. We believe our hospitals can effectively compete in this market due to location and specialty mix of our facilities. Our hospitals also have a higher portion of self pay business than the overall market. Self pay business is not influenced by the private insurers.

        In Spain, we face competition from several privately held independent hospitals and a few networks of hospitals that are owned by insurance companies. Insurance companies that own hospitals have the benefit of a captured market of their insured, including hospitals owned by Adesla, our primary competitor in Spain. These insurance companies compete with us in acquisitions of strategically placed hospitals in major cities. Other hospital networks are attempting to replicate our model and have begun to compete with us in the acquisition of hospitals. In our experience, sellers are typically the physicians that have built the hospitals, and most physicians prefer an independent position in a market rather than becoming a provider for an insurance company. We focus our efforts on partnering with physicians and assisting them in growing their business and medical practices by encouraging group rather than individual practices.

        Our hospitals compete with other providers in the Spanish market, including other private hospitals and hospitals operated by Spain's national health service. The national health coverage makes the hospitals operated by Spain's national health service accessible to the entire Spanish population. In contrast, private hospitals such as ours must negotiate agreements with third-party payors, which focus on services available to their members as well as pricing. We believe that the size of our operations in Spain has given us the ability to negotiate effectively with insurance companies.

15




Employees

        We employ approximately 3,300 persons, 2,700 of whom are full-time employees and 600 of whom are part-time employees. Of these employees, we employ approximately 1,400 in the United States, 600 in the United Kingdom and 1,300 in Spain. The physicians that affiliate with us and use our facilities are not our employees. However, we generally offer the physicians the opportunity to purchase equity interests in the facilities they use.


Professional and General Liability Insurance

        In the United States, we maintain professional liability insurance that provides coverage on a claims made basis of $1.0 million per incident (after a $50,000 deductible) and $3.0 million in annual aggregate amount per location with retroactive provisions upon policy renewal. We also maintain general liability insurance coverage of $1.0 million per occurrence and $2.0 million in annual aggregate amount per location, as well as business interruption insurance and property damage insurance. In addition, we maintain umbrella liability insurance in the aggregate amount of $20.0 million. In the United Kingdom, we maintain general public insurance in the amount of $5.0 million, malpractice insurance in the amount of $3.0 million and property and business interruption insurance. In Spain, we maintain general liability insurance coverage of $600,000 per accident and victim per year, per facility and $3.0 million at the group level and property and business interruption insurance. Our insurance policies are generally subject to annual renewals. Recent pressures within the insurance markets and industry have resulted in significant increases in costs for certain types of insurance and certain policyholders. We believe that we will be able to renew current policies or otherwise obtain comparable insurance coverage at reasonable rates. However, we have no control over the insurance markets and can provide no assurance that we will economically be able to maintain insurance similar to our current policies. The governing documents of each of our surgery centers require physicians who conduct surgical procedures at our surgery centers to maintain stated amounts of insurance.


Government Regulation

        The healthcare industry is subject to extensive regulation by federal, state and local governments. Government regulation affects our business by controlling growth, requiring licensing or certification of facilities, regulating how facilities are used, and controlling payment for services provided. Further, the regulatory environment in which we operate may change significantly in the future. While we believe we have structured our agreements and operations in material compliance with applicable law, there can be no assurance that we will be able to successfully address changes in the regulatory environment.

        Every state imposes licensing and other requirements on healthcare facilities. In addition, many states require regulatory approval, including certificates of need, before establishing or expanding various types of healthcare facilities, including surgery centers and private surgical hospitals, offering services or making capital expenditures in excess of statutory thresholds for healthcare equipment, facilities or programs. We may become subject to additional burdensome regulations as we expand our existing operations and enter new markets.

        In addition to extensive existing government healthcare regulation, there have been numerous initiatives on the federal and state levels for comprehensive reforms affecting the payment for and availability of healthcare services. We believe that these healthcare reform initiatives will continue during the foreseeable future. If adopted, some aspects of previously proposed reforms, such as further reductions in Medicare or Medicaid payments, or additional prohibitions on physicians' financial relationships with facilities to which they refer patients, could adversely affect us.

16



        We believe that our business operations materially comply with applicable law. However, we have not received a legal opinion from counsel or from any federal or state judicial or regulatory authority to this effect, and many aspects of our business operations have not been the subject of state or federal regulatory scrutiny or interpretation. Some of the laws applicable to us are subject to limited or evolving interpretations; therefore, a review of our operations by a court or law enforcement or regulatory authority might result in a determination that could have a material adverse effect on us. Furthermore, the laws applicable to us may be amended or interpreted in a manner that could have a material adverse effect on us. Our ability to conduct our business and to operate profitably will depend in part upon obtaining and maintaining all necessary licenses, certificates of need and other approvals, and complying with applicable healthcare laws and regulations.

        Capital expenditures for the construction of new facilities, the addition of beds or the acquisition of existing facilities may be reviewable by state regulators under statutory schemes that are sometimes referred to as certificate of need laws. States with certificate of need laws place limits on the construction and acquisition of healthcare facilities and the expansion of existing facilities and services. In these states, approvals are required for capital expenditures exceeding certain specified amounts and that involve certain facilities or services, including surgery centers and private surgical hospitals.

        State certificate of need laws generally provide that, prior to the addition of new beds, the construction of new facilities or the introduction of new services, a designated state health planning agency must determine that a need exists for those beds, facilities or services. The certificate of need process is intended to promote comprehensive healthcare planning, assist in providing high quality healthcare at the lowest possible cost and avoid unnecessary duplication by ensuring that only those healthcare facilities that are needed will be built.

        Typically, the provider of services submits an application to the appropriate agency with information concerning the area and population to be served, the anticipated demand for the facility or service to be provided, the amount of capital expenditure, the estimated annual operating costs, the relationship of the proposed facility or service to the overall state health plan and the cost per patient day for the type of care contemplated. The issuance of a certificate of need is based upon a finding of need by the agency in accordance with criteria set forth in certificate of need laws and state and regional health facilities plans. If the proposed facility or service is found to be necessary and the applicant to be the appropriate provider, the agency will issue a certificate of need containing a maximum amount of expenditure and a specific time period for the holder of the certificate of need to implement the approved project.

        Our healthcare facilities are also subject to state and local licensing regulations ranging from the adequacy of medical care to compliance with building codes and environmental protection laws. To assure continued compliance with these regulations, governmental and other authorities periodically inspect our facilities. The failure to comply with these regulations could result in the suspension or revocation of a healthcare facility's license.

        Our healthcare facilities receive accreditation from the Joint Commission on Accreditation of Healthcare Organizations or the Accreditation Association for Ambulatory Health Care, Inc., nationwide commissions which establish standards relating to the physical plant, administration, quality of patient care and operation of medical staffs of various types of healthcare facilities. Generally, our healthcare facilities must be in operation for at least six months before they are eligible for accreditation. As of December 31, 2002, all but our most recently opened or acquired healthcare facilities had been accredited by either the Joint Commission on Accreditation of Healthcare Organizations or the Accreditation Association for Ambulatory Health Care, Inc. Many managed care

17



companies and third-party payors require our facilities to be accredited in order to be considered a participating provider under their health plans.

        Medicare is a federally funded and administered health insurance program, primarily for individuals entitled to social security benefits who are 65 or older or who are disabled. Medicaid is a health insurance program jointly funded by state and federal governments that provides medical assistance to qualifying low income persons. Each state Medicaid program has the option to provide payment for surgery center services. All of the states in which we currently operate cover Medicaid surgery center services; however, these states may not continue to cover surgery center services and states into which we expand our operations may not cover or continue to cover surgery center services.

        Medicare payments for procedures performed at surgery centers are not based on costs or reasonable charges. Instead, Medicare prospectively determines fixed payment amounts for procedures performed at surgery centers. These amounts are adjusted for regional wage variations. The various state Medicaid programs also pay us a fixed payment for our services, which amount varies from state to state. A portion of our revenues are attributable to payments received from the Medicare and Medicaid programs. For the years ended December 31, 2000, 2001, and 2002 18%, 21% and 23%, respectively, of our domestic case volumes were attributable to Medicare and Medicaid payments.

        To participate in the Medicare program and receive Medicare payment, our facilities must comply with regulations promulgated by the Department of Health and Human Services. Among other things, these regulations, known as "conditions of participation," relate to the type of facility, its equipment, its personnel and its standards of medical care, as well as compliance with state and local laws and regulations. Our surgery centers must also satisfy the conditions of participation in order to be eligible to participate in the Medicaid program. All of our surgery centers and private surgical hospitals in the United States are certified or awaiting certification to participate in the Medicare program. These facilities are subject to annual on-site surveys to maintain their certification. Failure to comply with Medicare's conditions of participation may result in loss of program payment or other governmental sanctions. We have established ongoing quality assurance activities to monitor and ensure our facilities' compliance with these conditions of participation.

        The Department of Health and Human Services and the states in which we perform surgical procedures for Medicaid patients may revise the Medicare and Medicaid payments methods or rates in the future. Any such changes could have a negative impact on the reimbursements we receive for our surgical services from the Medicare program and the state Medicaid programs. We do not know at this time when or to what extent revisions to such payment methodologies will be implemented.

        As with most government programs, the Medicare and Medicaid programs are subject to statutory and regulatory changes, possible retroactive and prospective rate adjustments, administrative rulings, freezes and funding reductions, all of which may adversely affect the level of payments to our surgery centers. Reductions or changes in Medicare or Medicaid funding could significantly affect our results of operations. We cannot predict at this time whether additional healthcare reform initiatives will be implemented or whether there will be other changes in the administration of government healthcare programs or the interpretation of government policies that would adversely affect our business.

        State and federal laws regulate relationships among providers of healthcare services, including employment or service contracts and investment relationships. These restrictions include a federal

18


criminal law, referred to herein as the Anti-Kickback Statute, that prohibits offering, paying, soliciting, or receiving any form of remuneration in return for:

        A violation of the Anti-Kickback Statute constitutes a felony. Potential sanctions include imprisonment of up to five years, criminal fines of up to $25,000, civil money penalties of up to $50,000 per act plus three times the remuneration offered or three times the amount claimed and exclusion from all federally funded healthcare programs, including the Medicare and Medicaid programs. The applicability of these provisions to many business transactions in the healthcare industry has not yet been subject to judicial or regulatory interpretation.

        Pursuant to the Anti-Kickback Statute, and in an effort to reduce potential fraud and abuse relating to federal healthcare programs, the federal government has announced a policy of increased scrutiny of joint ventures and other transactions among healthcare providers. The Office of the Inspector General of the Department of Health and Human Services closely scrutinizes healthcare joint ventures involving physicians and other referral sources. In 1989, the Office of the Inspector General published a fraud alert that outlined questionable features of "suspect" joint ventures, and the Office of the Inspector General has continued to rely on fraud alerts in later pronouncements. The Office of the Inspector General has also published regulations containing numerous "safe harbors" that exempt some practices from enforcement under the Anti-Kickback Statute. These safe harbor regulations, if fully complied with, assure participants in particular types of arrangements that the Office of the Inspector General will not treat their participation as a violation of the Anti-Kickback Statute. The safe harbor regulations do not expand the scope of activities that the Anti- Kickback Statute prohibits, nor do they provide that failure to satisfy the terms of a safe harbor constitutes a violation of the Anti-Kickback Statute. The Office of the Inspector General has, however, indicated that failure to satisfy the terms of a safe harbor may subject an arrangement to increased scrutiny.

        Our partnerships and limited liability companies that are providers of services under the Medicare and Medicaid programs, and their respective limited partners and members, are subject to the Anti-Kickback Statute. A number of the relationships that we have established with physicians and other healthcare providers do not fit within any of the safe harbor regulations issued by the Office of the Inspector General. Of the 51 surgical facilities in the United States in which we hold an ownership interest, 49 are owned by partnerships, limited liability partnerships or limited liability companies, which include as partners or members physicians who perform surgical or other procedures at the facilities.

        On November 19, 1999, the Office of the Inspector General promulgated rules setting forth additional safe harbors under the Anti-Kickback Statute. The new safe harbors include a safe harbor applicable to surgery centers, referred to as the "surgery center safe harbor." The surgery center safe harbor generally protects ownership or investment interests in a center by physicians who are in a position to refer patients directly to the center and perform procedures at the center on referred patients, if certain conditions are met. More specifically, the surgery center safe harbor protects any payment that is a return on an ownership or investment interest to an investor if certain standards are met in one of four categories of ambulatory surgery centers (1) surgeon-owned surgery centers, (2) single-specialty surgery centers, (3) multi-specialty surgery centers, and (4) hospital/physician surgery centers.

19



        For multi-specialty ambulatory surgery centers, for example, the following standards, among others, apply:

        Similar standards apply to each of the remaining three categories of surgery centers set forth in the regulations. In particular, each of the four categories includes a requirement that no ownership interests be held by a non-physician or non-hospital investor if that investor is (a) employed by the center or another investor, (b) in a position to provide items or services to the center or any of its other investors, or (c) in a position to make or influence referrals directly or indirectly to the center or any of its investors.

        Since one of our subsidiaries is an investor in each partnership or limited liability company that owns one of our surgery centers, and since this subsidiary provides management and other services to the surgery center, our arrangements with physician investors do not fit within the specific terms of the surgery center safe harbor or any other safe harbor.

        In addition, because we do not control the medical practices of our physician investors or control where they perform surgical procedures, it is possible that the quantitative tests described above will not be met, or that other conditions of the surgery center safe harbor will not be met. Accordingly, while the surgery center safe harbor is helpful in establishing that a physician's investment in a surgery center should be considered an extension of the physician's practice and not as a prohibited financial relationship, we can give you no assurances that these ownership interests will not be challenged under the Anti-Kickback Statute. However, we believe that our arrangements involving physician ownership interests in our surgery centers should not fall within the activities prohibited by the Anti-Kickback Statute.

        While several federal court decisions have aggressively applied the restrictions of the Anti-Kickback Statute, they provide little guidance regarding the application of the Anti-Kickback Statute to our partnerships and limited liability companies. We believe that our operations do not violate the Anti-Kickback Statute. However, a federal agency charged with enforcement of the Anti-Kickback Statute might assert a contrary position. Further, new federal laws, or new interpretations of existing laws, might adversely affect relationships we have established with physicians or other healthcare providers or result in the imposition of penalties on us or some of our facilities. Even the assertion of a violation could have a material adverse effect upon us.

        Section 1877 of the Social Security Act, commonly known as the "Stark Law," prohibits physicians, subject to the exceptions described below, from referring Medicare or Medicaid patients to any entity providing "designated health services" in which the physician or an immediate family member has an ownership or investment interest or with which the physician or an immediate family member has entered into a compensation arrangement. These prohibitions, contained in the Omnibus Budget

20



Reconciliation Act of 1993, commonly known as "Stark II," amended prior federal physician self-referral legislation known as "Stark I" by expanding the list of designated health services to a total of eleven categories of health services. Persons who violate the Stark Law are subject to potential civil money penalties of up to $15,000 for each bill or claim submitted in violation of the Stark Law and $100,000 for participation in a "circumvention scheme" and exclusion from the Medicare and Medicaid programs. In addition, the Stark Law requires the refund of any Medicare and Medicaid payments received for designated health services that resulted from a prohibited referral.

        Ambulatory surgery is not specifically enumerated as a health service subject to this prohibition; however, some of the eleven designated health services under the Stark Law are among the specific services furnished by our surgery facilities. Final regulations interpreting Stark I, often referred to as the "Stark I regulations," were issued on August 14, 1995. On January 4, 2001 the Department of Health and Human Services published "Phase I" of the final regulations interpreting Stark II and modifying the Stark I regulations. The Department of Health and Human Services anticipates publishing "Phase II" of the regulations in the near future. The Phase I regulations, which in general took effect on January 4, 2002, address some of the ownership and investment interest exceptions and compensation arrangement exceptions found in the Stark Law. Under the Stark I regulations, clinical laboratory services provided by a surgery center are excepted from the Stark Law's self-referral prohibition, if these services are included in the surgery center's composite Medicare payment rate. The Phase I regulations take a different approach and exclude from the definition of "designated health services" any designated health services provided by a surgery center, if the services are included in the surgery center's composite Medicare payment rate. Therefore, under the Phase I regulations, the Stark Law's self-referral prohibition does not apply to designated health services provided by a surgery center, unless the surgery center separately bills Medicare for the services. We believe that our operations do not violate the Stark Law, as currently interpreted. However, the Department of Health and Human Services has indicated that it will further address the exception relating to services provided by a surgery center in Phase II of the regulations. Therefore, we cannot assure you that future regulatory changes will not result in us becoming subject to the Stark Law's self-referral prohibition.

        Three of our U.S. facilities, and one additional facility in the development stage, are surgical hospitals rather than outpatient surgery centers. Although there is an exemption for physician investments in surgical hospitals under the Stark Law (so long as it is an investment in the entire hospital and not just a department), the Office of Inspector General has not adopted any safe harbor regulations under the Anti-Kickback Statute for physician investments in surgical hospitals. Each of our surgical hospitals is held in partnership with physicians who are in a position to refer patients to the hospital. There can be no assurances that these relationships will not be found to violate the Anti-Kickback Statute or that there will not be regulatory or legislative changes that prohibit physician ownership of surgical hospitals."

        The federal government is authorized to impose criminal, civil and administrative penalties on any person or entity that files a false claim for payment from the Medicare or Medicaid programs. Claims filed with private insurers can also lead to criminal and civil penalties, including, but not limited to, penalties relating to violations of federal mail and wire fraud statutes. While the criminal statutes are generally reserved for instances of fraudulent intent, the government is applying its criminal, civil and administrative penalty statutes in an ever-expanding range of circumstances. For example, the government has taken the position that a pattern of claiming reimbursement for unnecessary services violates these statutes if the claimant merely should have known the services were unnecessary, even if the government cannot demonstrate actual knowledge. The government has also taken the position that claiming payment for low-quality services is a violation of these statutes if the claimant should have known that the care was substandard.

21


        Over the past several years, the government has accused an increasing number of healthcare providers of violating the federal False Claims Act. The False Claims Act prohibits a person from knowingly presenting, or causing to be presented, a false or fraudulent claim to the United States government. The statute defines "knowingly" to include not only actual knowledge of a claims falsity, but also reckless disregard for or intentional ignorance of the truth or falsity of a claim. Because our facilities perform hundreds of similar procedures a year for which they are paid by Medicare, and there is a relatively long statute of limitations, a billing error or cost reporting error could result in significant civil or criminal penalties.

        Under the "qui tam," or whistleblower, provisions of the False Claims Act, private parties may bring actions on behalf of the federal government. Such private parties, often referred to as relators, are entitled to share in any amounts recovered by the government through trial or settlement. Both direct enforcement activity by the government and whistleblower lawsuits have increased significantly in recent years and have increased the risk that a healthcare company, like us, will have to defend a false claims action, pay fines or be excluded from the Medicare and Medicaid programs as a result of an investigation resulting from a whistleblower case. Although we believe that our operations materially comply with both federal and state laws, they may nevertheless be the subject of a whistleblower lawsuit, or may otherwise be challenged or scrutinized by governmental authorities. A determination that we have violated these laws could have a material adverse effect on us.

        Many states, including those in which we do or expect to do business, have laws that prohibit payment of kickbacks or other remuneration in return for the referral of patients. Some of these laws apply only to services reimbursable under state Medicaid programs. However, a number of these laws apply to all healthcare services in the state, regardless of the source of payment for the service. Based on court and administrative interpretations of the federal Anti-Kickback Statute, we believe that the Anti-Kickback Statute prohibits payments only if they are intended to induce referrals. However, the laws in most states regarding kickbacks have been subjected to more limited judicial and regulatory interpretation than federal law. Therefore, we can give you no assurances that our activities will be found to be in compliance with these laws. Noncompliance with these laws could subject us to penalties and sanctions and have a material adverse effect on us.

        A number of states, including those in which we do or expect to do business, have enacted physician self-referral laws that are similar in purpose to the Stark Law but which impose different restrictions. Some states, for example, only prohibit referrals when the physician's financial relationship with a healthcare provider is based upon an investment interest. Other state laws apply only to a limited number of designated health services. Some states do not prohibit referrals, but require that a patient be informed of the financial relationship before the referral is made. We believe that our operations are in material compliance with the physician self-referral laws of the states in which our facilities are located.

        The Health Insurance Portability and Accountability Act of 1996 contains, among other measures, provisions that may require many organizations, including us, to implement very significant and potentially expensive new computer systems and business procedures designed to protect each patient's individual healthcare information. The Health Insurance Portability and Accountability Act of 1996 requires the Department of Health and Human Services to issue rules to define and implement patient privacy and security standards. Among the standards that the Department of Health and Human

22


Services will adopt pursuant to the Health Insurance Portability and Accountability Act of 1996 are standards for the following:

        On August 17, 2000, the Department of Health and Human Services finalized the transaction standards. The Administrative Simplification and Compliance Act extended the date by which we must comply with the transaction standards to October 16, 2003, provided we submit a compliance plan to the Secretary of Health and Human Services by October 16, 2002. We submitted a compliance plan by October 16, 2002. The transaction standards will require us to use standard code sets established by the rule when transmitting health information in connection with some transactions, including health claims and health payment and remittance advices.

        On February 20, 2003, the Department of Health and Human Services issued a final rule that establishes, in part, standards for the security of health information by health plans, healthcare clearinghouses and healthcare providers that maintain or transmit any health information in electronic form, regardless of format. We are an affected entity under the rule. These security standards require affected entities to establish and maintain reasonable and appropriate administrative, technical and physical safeguards to ensure integrity, confidentiality and the availability of the information. The security standards were designed to protect the health information against reasonably anticipated threats or hazards to the security or integrity of the information and to protect the information against unauthorized use or disclosure. Although the security standards do not reference or advocate a specific technology, and affected entities have the flexibility to choose their own technical solutions, we expect that the security standards will require us to implement significant systems and protocols. The compliance date for the initial implementation of the standards set forth in the security rule is April 20, 2005.

        Compliance with these standards will require significant commitment and action by us. We have appointed members of our management team to direct our compliance with these standards. Although we and other covered entities generally are not required to be in compliance with these standards until April 20, 2005, implementation will require us to conduct extensive preparation and make significant expenditures. Although we estimate the total costs of implementing these regulations to be $200,000, because the security rule is quite new, we cannot yet predict the total financial impact of the regulations on our operations.

        On December 28, 2000, the Department of Health and Human Services published a final rule establishing standards for the privacy of individually identifiable health information. This rule was amended May 31, 2002 and August 14, 2002. These privacy standards apply to all health plans, all healthcare clearinghouses and many healthcare providers, including healthcare providers that transmit health information in an electronic form in connection with certain standard transactions. We are a covered entity under the final rule. The privacy standards protect individually identifiable health information held or disclosed by a covered entity in any form, whether communicated electronically, on paper or orally. These standards not only require our compliance with rules governing the use and disclosure of protected health information, but they also require us to impose those rules, by contract, on any business associate to whom such information is disclosed. A violation of the privacy standards could result in civil money penalties of $100 per incident, up to a maximum of $25,000 per person per year per standard. The final rule also provides for criminal penalties of up to $50,000 and one year in

23



prison for knowingly and improperly obtaining or disclosing protected health information, up to $100,000 and five years in prison for obtaining protected health information under false pretenses, and up to $250,000 and ten years in prison for obtaining or disclosing protected health information with the intent to sell, transfer or use such information for commercial advantage, personal gain or malicious harm. The compliance date for the privacy rule is April 14, 2003.


European Union

        The European Commission's Directive on Data Privacy went into effect in October 1998 and prohibits the transfer of personal data to non-European Union countries that do not meet the European "adequacy" standard for privacy protection. The European Union privacy legislation requires, among other things, the creation of government data protection agencies, registration of databases with those agencies, and in some instances prior approval before personal data processing may begin.

        The U.S. Department of Commerce, in consultation with the European Commission, recently developed a "safe harbor" framework to protect data transferred in trans Atlantic businesses like ours. The safe harbor provides a way for us to avoid experiencing interruptions in our business dealings in the European Union. It also provides a way to avoid prosecution by European authorities under European privacy laws. By certifying to the safe harbor, we will notify the European Union organizations that we provide "adequate" privacy protection, as defined by European privacy laws. To certify to the safe harbor, we must adhere to seven principles. These principles relate to notice, choice, onward transfer or transfers to third parties, access, security, data integrity and enforcement.

        We intend to formulate and execute programs that will satisfy the requirements of the safe harbor. Even if we are able to formulate programs that attempt to meet these objectives, we may not be able to execute them successfully, which could have a material adverse effect on our revenues, profits or results of operations.

        Under the Spanish General Health Act and related regulations, private hospitals must report periodically to the applicable health authorities. These reports, which describe a hospital's activities, provide a method to identify and control epidemics. Private hospitals in Spain must obtain a number of licenses, permits and authorizations, including those required to begin operating the facility and to dispense drugs. In addition, private hospitals are subject to regular inspections by the health and administrative authorities to ensure compliance with applicable regulations. Private hospitals must register their personal databases with the Data Protection Agency. The Law of Personal Data Protection provides specific protection for the health information portion of this personal data. Private hospitals must adopt the necessary measures to ensure the safety of the personal data. Violations of these regulations could subject the hospital to administrative fines and civil and criminal liability. Administrative fines range from 3,000 Euros (approximately $3,000) to 600,000 Euros (approximately $600,000), or five times the value of the products and services that are the subject of the violation, depending on the seriousness of the violation. Health and administrative authorities may also close a private hospital for up to five years for serious violations. A violation that endangers the public health is a criminal offense. We believe that our operations in Spain are in material compliance with the laws referred to in this paragraph.

        While there is no specific anti kickback legislation in the United Kingdom that is unique to the medical profession, general criminal legislation prohibits bribery and corruption. Our private surgical hospitals in the United Kingdom do not pay commissions to or share profits with referring physicians,

24


who invoice patients or insurers directly for fees relating to the provision of their services. Private surgical hospitals in the United Kingdom are required to register with the local Social Services Authority pursuant to the Care Standards Act of 2000, which provides for regular inspections of the facility by the registering authority. The operation of a private surgical hospital without registration is a criminal offense. Under the Misuse of Drugs Act 1971, the supply, possession or production of controlled drugs without a license from the Secretary of State is a criminal offense. The Data Protection Act 1998 requires private surgical hospitals to register as "data controllers." The processing of personal data, such as patient information and medical records, without prior registration is a criminal offense. We believe that our operations in the United Kingdom are in material compliance with the laws referred to in this paragraph.


Risk Factors

        An investment in United Surgical Partners International, Inc. involves certain risks. You should carefully read the risks and uncertainties described below and the other information included in this report.


We depend on payments from third party payors, including government healthcare programs. If these payments are reduced, our revenue will decrease.

        We are dependent upon private and governmental third party sources of payment for the services provided to patients in our surgery centers and private surgical hospitals. The amount of payment a surgery center or private surgical hospital receives for its services may be adversely affected by market and cost factors as well as other factors over which we have no control, including Medicare and Medicaid regulations and the cost containment and utilization decisions of third party payors. In the United Kingdom and Spain, a significant portion of our revenues result from referrals of patients to our hospitals by the national health system. We have no control over the number of patients that are referred to the private sector annually. Fixed fee schedules, capitation payment arrangements, exclusion from participation in managed care programs or other factors affecting payments for healthcare services over which we have no control could also cause a reduction in our revenues.


If we are unable to acquire and develop additional surgery centers or private surgical hospitals on favorable terms, we may be unable to execute our acquisition and development strategy, which could limit our future growth.

        Our strategy is to increase our revenues and earnings by continuing to acquire surgical facility companies, groups of surgical facilities and individual surgical facilities and to develop additional surgical facilities. Our efforts to execute our acquisition and development strategy may be affected by our ability to identify suitable candidates and negotiate and close acquisition and development transactions. We are currently evaluating potential acquisitions and development projects and expect to continue to evaluate acquisitions and development projects in the foreseeable future. The surgical facilities we develop typically incur losses in their early months of operation and, until their case loads grow, they generally experience lower total revenues and operating margins than established surgical facilities. We expect that our development candidates will initially experience similar losses and lower revenues and operating margins. Historically, each of our newly developed facilities has generated positive cash flow within the first 12 months of operations. We may not be successful in acquiring other companies or additional surgical facilities, developing surgical facilities or achieving satisfactory operating results at acquired or newly developed facilities. Further, the companies or assets we acquire in the future may not ultimately produce returns that justify our related investment. If we are not able to execute our acquisition and development strategy, our ability to increase revenues and earnings through future growth would be impaired.

25




If we incur material liabilities as a result of acquiring companies or surgical facilities, our operating results could be adversely affected.

        Although we seek indemnification from prospective sellers covering unknown or contingent liabilities, we may acquire companies and surgical facilities that have material liabilities for failure to comply with healthcare laws and regulations or other past activities. Although we maintain professional and general liability insurance, we do not currently maintain insurance specifically covering any unknown or contingent liabilities that may have occurred prior to the acquisition of companies and surgical facilities. If we incur these liabilities and are not indemnified or insured for them, our operating results and financial condition could be adversely affected.


If we are unable to manage growth, we may be unable to achieve our growth strategy.

        We have acquired interests in or developed all of our surgery centers and private surgical hospitals since February 1998. We expect to continue to expand our operations in the future. As a young company, our rapid growth has placed, and will continue to place, increased demands on our management, operational and financial information systems and other resources. Further expansion of our operations will require substantial financial resources and management attention. To accommodate our past and anticipated future growth, and to compete effectively, we will need to continue to implement and improve our management, operational and financial information systems and to expand, train, manage and motivate our workforce. Our personnel, systems, procedures or controls may not be adequate to support our operations in the future. Further, focusing our financial resources and management attention on the expansion of our operations may negatively impact our financial results. Any failure to implement and improve our management, operational and financial information systems, or to expand, train, manage or motivate our workforce, could reduce or prevent our growth.


We depend on our relationships with not-for-profit healthcare systems. If we are not able to maintain our strategic alliances with these not-for-profit healthcare systems, or enter into new alliances, we may be unable to implement our business strategies successfully.

        Our domestic business depends in part upon the efforts and success of the not-for-profit healthcare systems with which we have strategic alliances and the strength of our alliances with those healthcare systems. Our business could be adversely affected by any damage to those healthcare systems' reputations or to our alliances with them. We may not be able to maintain our existing alliance agreements on terms and conditions favorable to us or enter into alliances with additional not-for-profit healthcare systems. If we are unable to maintain our existing strategic alliances on terms favorable to us or enter into alliances with additional not-for-profit healthcare systems, we may be unable to implement our business strategies successfully.


We depend on our relationships with the physicians who use our facilities. Our ability to provide medical services at our facilities would be impaired and our revenues reduced if we are not able to maintain these relationships.

        Our business depends upon the efforts and success of the physicians who provide medical services at our facilities and the strength of our relationships with these physicians. Our revenues would be reduced if we lost our relationship with one or more key physicians or group of physicians or such physicians or groups reduce their use of our facilities. In addition, any failure of these physicians to maintain the quality of medical care provided or to otherwise adhere to professional guidelines at our surgical facilities or any damage to the reputation of a key physician or group of physicians could damage our reputation, subject us to liability and significantly reduce our revenues.

26




Our European operations, which we plan to expand, are subject to unique risks. If any of these events actually occur, our financial results could be adversely affected.

        Our international operations are located in Spain and the United Kingdom. We expect that revenue from our European operations will continue to account for a significant percentage of our total revenue. We intend to pursue additional acquisitions in Spain and the United Kingdom. Expansion of our European operations will require substantial financial resources and management attention. This focus of financial resources and management attention could have an adverse effect on our financial results. Our European operations are subject, and as they continue to develop may become increasingly subject, to risks such as:

These or other factors could have a material adverse effect on our ability to successfully operate in Europe and our financial condition and operations.


Our significant indebtedness could limit our flexibility.

        We are substantially leveraged and will continue to have significant indebtedness in the future. Our acquisition and development program requires substantial capital resources, estimated to range from $35.0 to $50.0 million per year over the next three years, although the range could be exceeded if attractive multi-facility acquisition opportunities are identified. The operations of our existing surgical facilities also require ongoing capital expenditures.

        We currently have a $115.0 million revolving credit facility and $47.6 million in cash. Based solely on historical reported consolidated financial results, approximately $39.0 million was available for borrowing at December 31, 2002. Maximum availability under the facility is based upon pro forma EBITDA including EBITDA from acquired entities. Assuming historical purchase multiples of EBITDA of potential acquisition targets approximately $84.0 million would be available for borrowing as of December 31, 2002. We will need to incur additional indebtedness to fund future acquisitions, developments and capital expenditures. However, we may be unable to obtain sufficient financing on terms satisfactory to us, or at all. As a result, our acquisition and development activities would have to be curtailed or eliminated and our financial results would be adversely affected.

        The degree to which we are leveraged could have other important consequences to you, including the following:

27



Our revenues may be reduced by changes in payment methods or rates under the Medicare or Medicaid programs.

        The Department of Health and Human Services and the states in which we perform surgical procedures for Medicaid patients may revise the Medicare and Medicaid payment methods or rates in the future. Any such changes could have a negative impact on the reimbursements we receive for our surgical services from the Medicare program and the state Medicaid programs. We do not know at this time when or to what extent revisions to such payment methodologies will be implemented.


If we are unable to negotiate contracts and maintain satisfactory relationships with managed care organizations or other third party payors, our revenues may decrease.

        Our competitive position has been, and will continue to be, affected by initiatives undertaken during the past several years by major domestic purchasers of healthcare services, including federal and state governments, insurance companies and employers, to revise payment methods and monitor healthcare expenditures in an effort to contain healthcare costs. As a result of these initiatives, managed care companies such as health maintenance and preferred provider organizations, which offer prepaid and discounted medical service packages, represent a growing segment of healthcare payors, the effect of which has been to reduce domestic healthcare facility revenue growth. Similarly, in the United Kingdom, most patients at private surgical hospitals have private healthcare insurance, either paid for by the patient or received as part of their employment compensation. Our private surgical hospitals in the United Kingdom contract with healthcare insurers on an annual basis to provide services to insured patients.

        Our private surgical hospitals in Spain contract with healthcare insurers on an annual basis to provide services to insured patients. As the majority of our revenues in Spain are derived from private insurance companies, the annual negotiation of price increases is very important to the profitability of our hospitals in that country. In addition, our Spanish hospitals contract with the Spanish public healthcare system, which awards contracts based on a hospital's satisfaction of specified criteria. The Spanish public healthcare system has the right to give priority to hospitals owned by non-profit entities if the efficiency, quality and cost conditions of these entities are comparable to those of for profit hospitals. Our contracts with the Spanish public healthcare system typically have a term of less than one year and are renewable at the sole discretion of the Spanish public healthcare system. Any termination of an existing third party contract could result in a significant loss of revenues and could have a material adverse effect on us.

        As an increasing percentage of domestic patients become subject to healthcare coverage arrangements with managed care payors, we believe that our success will continue to depend upon our ability to negotiate favorable contracts on behalf of our facilities with managed care organizations, employer groups and other private third party payors. If we are unable to enter into these arrangements on satisfactory terms in the future we could be adversely affected. Many of these payors already have existing provider structures in place and may not be able or willing to change their provider networks. Similarly, if we fail to negotiate contracts with healthcare insurers in the United Kingdom and Spain on favorable terms, or if we fail to remain on insurers' networks of approved hospitals, such failure could have a material adverse effect on us. We could also experience a material

28



adverse effect to our operating results and financial condition as a result of the termination of existing third party payor contracts.


Efforts to regulate the construction, acquisition or expansion of healthcare facilities could prevent us from acquiring additional surgery centers or private surgical hospitals, renovating our existing facilities or expanding the breadth of services we offer.

        Many states in the United States require prior approval for the construction, acquisition or expansion of healthcare facilities or expansion of the services they offer. When considering whether to approve such projects, these states take into account the need for additional or expanded healthcare facilities or services. In a number of states in which we operate, including Alabama, Georgia, Florida, Tennessee and New York, we are required to obtain certificates of need for capital expenditures exceeding a prescribed amount, changes in bed capacity or services offered and under various other circumstances. Following a period of decline, the number of states requiring certificates of need is once again on the rise as state legislators are looking at this process as one way to control rising healthcare costs. Other states in which we now or may in the future operate may adopt certificate of need legislation or regulatory provisions. Our costs of obtaining a certificate of need have ranged up to $500,000. Spain also requires prior approval for the construction or expansion of healthcare facilities. In addition, private surgical hospitals in Spain must obtain a number of licenses, including a license to operate a pharmacy or to perform tests using radioactive materials. Although we have not previously been denied a certificate of need, we may not be able to obtain the certificates of need or other required approvals for additional or expanded facilities or services in the future. In addition, at the time we acquire a facility, we may agree to replace or expand the acquired facility. If we are unable to obtain the required approvals, we may not be able to acquire additional surgery centers or private surgical hospitals, expand the healthcare services provided at these facilities or replace or expand acquired facilities.


New federal and state legislative and regulatory initiatives relating to patient privacy and electronic data security could require us to expend substantial sums acquiring and implementing new information and transaction systems, which could negatively impact our financial results.

        There are currently numerous legislative and regulatory initiatives at the U.S. state and federal levels addressing patient privacy concerns and standards for the exchange of electronic health information. These provisions are intended to enhance patient privacy and the effectiveness and efficiency of healthcare claims and payment transactions. In particular, the Administrative Simplification Provisions of the Health Insurance Portability and Accountability Act of 1996 may require us to acquire and implement expensive new computer systems and to adopt business procedures designed to protect the privacy of each of our patient's individual health information.

        On August 17, 2000, the Department of Health and Human Services issued final regulations establishing electronic data transmission standards that healthcare providers must use when submitting or receiving certain healthcare data electronically. Compliance with these regulations is required by October 16, 2002. However, on December 27, 2001, President Bush signed into law the Administrative Simplification Compliance Act, which requires that, by October 16, 2002, covered entities must either: (1) be in compliance with the electronic data transmission standards; or (2) submit a summary plan to the Secretary of Health and Human Services describing how the entity will come into full compliance with the standards by October 16, 2003. We submitted a summary plan to the Secretary by October 16, 2002 and intend to comply with the standards by October 16, 2003. We cannot predict the impact that the final regulations, when fully implemented, will have on us.

        The Administrative Simplification Provisions of the Health Insurance Portability and Accountability Act also require the Department of Health and Human Services to adopt standards to protect the security and privacy of health-related information. Proposed security standards were published on

29



August 12, 1998, but they have not been finalized. The proposed security standards would require healthcare providers to implement organizational and technical practices to protect the security of patient information. Once the security regulations are finalized, we will have approximately two years to comply with such regulations.

        In addition, on December 28, 2000, the Department of Health and Human Services released final regulations regarding the privacy of healthcare information. Although these privacy regulations were effective April 14, 2001, compliance with these regulations is not required until April 14, 2003. The privacy regulations extensively regulate the use and disclosure of individually identifiable healthcare information, whether communicated electronically, on paper or verbally. The regulations also provide patients with significant new rights related to understanding and controlling how their health information is used or disclosed. We believe that policies and procedures will be in place to comply with these regulations within the time requirements.

        These regulations are expected to have a financial impact on the healthcare industry because they impose extensive new requirements and restrictions on the use and disclosure of identifiable patient information. We estimate the total cost of these systems and procedures to be $200,000. However, because of the proposed nature of the security regulations, we cannot predict the total financial or other impact of these regulations on our business and compliance with these regulations could require us to spend substantial sums, which could negatively impact our financial results. We believe that we are in material compliance with existing state and federal regulations relating to patient privacy. However, if we fail to comply with the newly released regulations, we could suffer civil penalties up to $25,000 per calendar year for each violation and criminal penalties with fines up to $250,000 per violation.


If we fail to comply with applicable laws and regulations, we could suffer penalties or be required to make significant changes to our operations.

        We are subject to many laws and regulations at the federal, state and local government levels in the domestic and European jurisdictions in which we operate. These laws and regulations require that our healthcare facilities meet various licensing, certification and other requirements, including those relating to:

        We believe that we are in material compliance with applicable laws and regulations. However, if we fail or have failed to comply with applicable laws and regulations, we could suffer civil or criminal penalties, including the loss of our licenses to operate and our ability to participate in Medicare, Medicaid and other government sponsored healthcare programs. A number of initiatives have been proposed during the past several years to reform various aspects of the healthcare system, both domestically and in the European jurisdictions in which we operate. In the future, different interpretations or enforcement of existing or new laws and regulations could subject our current practices to allegations of impropriety or illegality, or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses. Current or future

30



legislative initiatives or government regulation may have a material adverse effect on our operations or reduce the demand for our services.

        In pursuing our growth strategy, we may expand our presence into new geographic markets, including additional foreign countries. In entering a new geographic market, we will be required to comply with laws and regulations of jurisdictions that may differ from those applicable to our current operations. If we are unable to comply with these legal requirements in a cost-effective manner, we may be unable to enter new geographic markets.


If a federal or state agency asserts a different position or enacts new laws or regulations regarding illegal remuneration under the Medicare or Medicaid programs, we may be subject to civil and criminal penalties, experience a significant reduction in our revenues or be excluded from participation in the Medicare and Medicaid programs.

        The federal Anti-Kickback Statute prohibits the offer, payment, solicitation or receipt of any form of remuneration in return for referring items or services payable by Medicare, Medicaid, or any other federally funded healthcare program. Additionally, the Anti-Kickback Statute prohibits any form of remuneration in return for purchasing, leasing, or ordering or arranging for or recommending the purchasing, leasing or ordering of items or services payable by Medicare, Medicaid or any other federally funded healthcare program. The Anti-Kickback Statute is very broad in scope and many of its provisions have not been uniformly or definitively interpreted by existing case law or regulations. Violations of the Anti-Kickback Statute may result in substantial civil or criminal penalties, including criminal fines of up to $25,000 and civil penalties of up to $50,000 for each violation, plus three times the remuneration involved or the amount claimed and exclusion from participation in the Medicare and Medicaid programs. The exclusion, if applied to our surgery centers or private surgical hospitals, could result in significant reductions in our revenues which could have a material adverse effect on our business.

        In July 1991, the Department of Health and Human Services issued final regulations defining various "safe harbors." Two of the safe harbors issued in 1991 apply to business arrangements similar to those used in connection with our surgery centers and private surgical hospitals: the "investment interest" safe harbor and the "personal services and management contracts" safe harbor. However, the structure of the limited partnerships and limited liability companies operating our surgery centers and private surgical hospitals, as well as our various business arrangements involving physician group practices, do not satisfy all of the requirements of either safe harbor. Therefore, our business arrangements with our surgery centers, private surgical hospitals and physician groups did not and do not qualify for "safe harbor" protection from government review or prosecution under the Anti-Kickback Statute. Since there is no legal requirement that transactions with referral sources fit within a safe harbor, a business arrangement that does not substantially comply with the relevant safe harbor is not necessarily illegal under the Anti-Kickback Statute.

        On November 19, 1999, the Department of Health and Human Services promulgated final regulations creating additional safe harbor provisions, including a safe harbor that applies to physician ownership of or investment interests in surgery centers. The surgery center safe harbor protects four types of investment arrangements: (1) surgeon owned surgery centers; (2) single specialty surgery centers; (3) multi-specialty surgery centers; and (4) hospital/physician surgery centers. Each category has its own requirements with regard to what type of physician may be an investor in the surgery center. In addition to the physician investor, the categories permit an "unrelated" investor, who is a person or entity that is not in a position to provide items or services related to the surgery center or its investors. Our business arrangements with our surgery centers typically consist of one of our subsidiaries being an investor in each limited partnership or limited liability company that owns the surgery center, in addition to providing management and other services to the surgery center. As a

31



result, these business arrangements do not comply with all the requirements of the surgery center safe harbor, and, therefore, are not immune from government review or prosecution.

        Although we believe that our business arrangements do not violate the Anti-Kickback Statute, a government agency or a private party may assert a contrary position. Additionally, new domestic federal or state laws may be enacted that would cause our relationships with the physician investors to become illegal or result in the imposition of penalties against us or our facilities. If any of our business arrangements with physician investors were deemed to violate the Anti-Kickback Statute or similar laws, or if new domestic federal or state laws were enacted rendering these arrangements illegal, our business could be adversely affected.

        Also, most of the states in which we operate have adopted anti-kickback laws, many of which apply more broadly to all third-party payors, not just to federal healthcare programs. Many of the state laws do not have regulatory safe harbors comparable to the federal provisions and have only rarely been interpreted by the courts or other governmental agencies. If our arrangements were found to violate any of these anti-kickback laws, we could be subject to significant civil and criminal penalties that could adversely affect our business.


If physician self-referral laws are interpreted differently or if other legislative restrictions are issued, we could incur significant sanctions and loss of reimbursement revenues.

        The U.S. federal physician self-referral law, commonly referred to as the Stark Law, prohibits a physician from making a referral for a designated health service to an entity if the physician or a member of the physician's immediate family has a financial relationship with the entity. The original Stark Law, commonly known as Stark I, only addressed referrals involving clinical laboratory services. However, in 1995 additional legislation, commonly known as Stark II, expanded the ban on self-referrals by adding the following services to the definition of "designated health services": physical therapy services; occupational therapy services; radiology services; radiation therapy services and supplies; durable medical equipment and supplies; parenteral and enteral nutrients, equipment and supplies; prosthetics, orthotics, and prosthetic devices and supplies; home health services; outpatient prescription drugs; and inpatient and outpatient hospital services.

        The Department of Health and Human Services issued a portion of the Stark II final rule, which it called "Phase I," on January 4, 2001. The Phase I regulations, which generally took effect on January 4, 2002, address some of the ownership and investment interest exceptions and compensation arrangement exceptions found in the Stark Law. Phase II of the final rule will address, among other things, any comments made in response to the Phase I final rule, the remaining ownership and investment interest exceptions and compensation arrangement exceptions, the reporting requirements, sanctions and the Stark Law's application to the Medicaid program. It is not known when the Phase II final rule will be issued. Under current regulations interpreting Stark I and under the Phase I regulations, services that would otherwise constitute designated health services, but that are paid by Medicare as part of the surgery center payment rate, are not designated health services for purposes of the Stark Law.

        In addition, we believe that physician ownership of surgery centers is not prohibited by similar self-referral statutes enacted at the state level. However, the Stark Law and similar state statutes are subject to different interpretations with respect to many important provisions. Violations of these self-referral laws may result in substantial civil or criminal penalties, including large civil monetary penalties and exclusion from participation in the Medicare and Medicaid programs. Exclusion of our surgery centers or private surgical hospitals from these programs through future judicial or agency interpretation of existing laws or additional legislative restrictions on physician ownership or investments in healthcare entities could result in significant loss of reimbursement revenues.

        In Spain, there is legislation that prohibits physicians who have contracted with the Spanish public healthcare system on an exclusive basis from rendering services in a private hospital. Spanish legislation

32



also prohibits physicians rendering services within the Spanish public healthcare system on a non-exclusive basis from rendering services to Spanish public healthcare system patients in private hospitals such as ours. Violations of these laws could result in administrative fines and termination of our alliance with the Spanish public healthcare system. If the physicians who use our Spanish facilities violate these regulations and their or our contracts are terminated with the Spanish public healthcare system, preventing them from continuing to use our facilities, we could experience a significant loss of revenues in Spain.


Companies within the healthcare industry continue to be the subject of federal and state investigations, which increases the risk that we may become subject to investigations in the future.

        Both federal and state government agencies, as well as private payors, have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare organizations. These investigations relate to a wide variety of topics, including the following:

        In addition, the Office of the Inspector General of the Department of Health and Human Services and the Department of Justice have, from time to time, undertaken national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. Moreover, another trend impacting healthcare providers is the increased use of the federal False Claims Act, particularly by individuals who bring actions under that law. Such "qui tam" or "whistleblower" actions allow private individuals to bring actions on behalf of the government alleging that a healthcare provider has defrauded the federal government. If the government intervenes and prevails in the action, the defendant may be required to pay three times the actual damages sustained by the government, plus mandatory civil monetary penalties of between $5,500 and $11,000 for each false claim submitted to the government. As part of the resolution of a qui tam case, the party filing the initial complaint may share in a portion of any settlement or judgment. If the government does not intervene in the action, the qui tam plaintiff may pursue the action independently. Additionally, some states have adopted similar whistleblower and false claims provisions. Although companies in the healthcare industry have been, and may continue to be, subject to qui tam actions, we are unable to predict the impact of such actions on our business, financial position or results of operations.


If laws governing the corporate practice of medicine change, we may be required to restructure some of our domestic relationships which may result in significant costs to us and divert other resources.

        The laws of various domestic jurisdictions in which we operate or may operate in the future do not permit business corporations to practice medicine, exercise control over physicians who practice medicine or engage in various business practices, such as fee-splitting with physicians. The interpretation and enforcement of these laws vary significantly from state to state. We are not required to obtain a license to practice medicine in any jurisdiction in which we own or operate a surgery center or private surgical hospital because our facilities are not engaged in the practice of medicine. The physicians who utilize our facilities are individually licensed to practice medicine. In most instances, the physicians and physician group practices performing medical services at our facilities do not have investment or business relationships with us other than through the physicians' ownership interests in the partnerships or limited liability companies that own and operate our facilities and the service agreements we have with some of those physicians.

33



        As a result of our acquisition of OrthoLink, we provide management services to a number of physicians and physician group practices affiliated with OrthoLink. Although we believe that our arrangements with these and other physicians and physician group practices comply with applicable laws, a government agency charged with enforcement of these laws, or a private party, might assert a contrary position. If our arrangements with these physicians and physician group practices were deemed to violate state corporate practice of medicine, fee-splitting or similar laws, or if new laws are enacted rendering our arrangements illegal, we may be required to restructure these arrangements, which may result in significant costs to us and divert other resources.


If domestic regulations change, we may be obligated to purchase some or all of the ownership interests of the physicians affiliated with us.

        Upon the occurrence of various fundamental regulatory changes, we will be obligated to purchase some or all of the ownership interests of the physicians affiliated with us in the limited partnerships or limited liability companies that own and operate our surgery centers and private surgical hospitals. The regulatory changes that could create this obligation include changes that:

At this time, we are not aware of any regulatory amendments or proposed changes that would trigger this obligation. Some of our limited partnership and limited liability company agreements allow us to use shares of our common stock as consideration for the purchase of a physician's ownership interest. The use of shares of our common stock for that purpose would dilute the ownership interests of our common stockholders. In the event that we are required to purchase all of the physicians' ownership interests and our common stock does not maintain a sufficient valuation, we could be required to use our cash resources for the acquisitions, the total cost of which we estimate to be up to $100.0 million. The creation of these obligations and the possible termination of our affiliation with these physicians could have a material adverse effect on us.


If we become subject to significant legal actions, we could be subject to substantial uninsured liabilities.

        In recent years, physicians, hospitals and other healthcare providers have become subject to an increasing number of legal actions alleging malpractice, product liability or related legal theories. Many of these actions involve large monetary claims and significant defense costs. We do not employ any of the physicians who conduct surgical procedures at our facilities and the governing documents of each of our surgery centers require physicians who conduct surgical procedures at our surgery centers to maintain stated amounts of insurance. Additionally, to protect us from the cost of these claims, we maintain professional malpractice liability insurance and general liability insurance coverage in amounts and with deductibles that we believe to be appropriate for our operations. If we become subject to claims, however, our insurance coverage may not cover all claims against us or continue to be available at a cost allowing us to maintain adequate levels of insurance. If one or more successful claims against us were not covered by or exceeded the coverage of our insurance, we could be adversely affected.

34




If we are unable to effectively compete for physicians, strategic relationships, acquisitions and managed care contracts, our business could be adversely affected.

        The healthcare business is highly competitive. We compete with other healthcare providers, primarily hospitals, in recruiting physicians and contracting with managed care payors in each of our markets. In Spain and the United Kingdom, we also compete with these countries' national health systems in recruiting healthcare professionals. There are major unaffiliated hospitals in each market in which we operate. These hospitals have established relationships with physicians and payors. In addition, other companies either are currently in the same or similar business of developing, acquiring and operating surgery centers and private surgical hospitals or may decide to enter our business. Many of these companies have greater financial, research, marketing and staff resources than we do. We may also compete with some of these companies for entry into strategic relationships with not-for-profit healthcare systems and healthcare professionals. If we are unable to compete effectively with any of these entities, we may be unable to implement our business strategies successfully and our business could be adversely affected.


Because we have a limited operating history and our senior management has been key to our growth, we may be adversely affected if we lose any member of our senior management.

        We are highly dependent on our senior management, including Donald E. Steen, our chairman and chief executive officer, and William H. Wilcox, our president. Although we have employment agreements with Mr. Steen and Mr. Wilcox, we do not maintain "key man" life insurance policies on any of our officers. Because our senior management has contributed greatly to our growth since inception, the loss of key management personnel or our inability to attract, retain and motivate sufficient numbers of qualified management personnel could have a material adverse effect on us.


We may have a special legal responsibility to the holders of ownership interests in the entities through which we own surgical facilities, and that responsibility may prevent us from acting solely in our own best interests or the interests of our stockholders.

        Our ownership interests in surgery centers and private surgical hospitals generally are held through limited partnerships, limited liability partnerships or limited liability companies. We typically maintain an interest in a limited partnership, limited liability partnership or limited liability company in which physicians or physician practice groups hold limited partnership, limited liability partnership or membership interests. As general partner or manager of these entities, we may have a special responsibility, known as a fiduciary duty, to manage these entities in the best interests of the other interest holders. We also have a duty to operate our business for the benefit of our stockholders. As a result, we may encounter conflicts between our responsibility to the other interest holders and our responsibility to our stockholders. For example, we have entered into management agreements to provide management services to all but one of our domestic surgery centers in exchange for a fee. Disputes may arise as to the nature of the services to be provided or the amount of the fee to be paid. In these cases, we are obligated to exercise reasonable, good faith judgment to resolve the disputes and may not be free to act solely in our own best interests or the interests of our stockholders. Disputes may also arise between us and our affiliated physicians with respect to a particular business decision or regarding the interpretation of the provisions of the applicable limited partnership agreement or limited liability company agreement. If we are unable to resolve a dispute on terms favorable or satisfactory to us, our business may be adversely affected.

35




We do not have exclusive control over the distribution of revenues from some of our domestic operating entities and may be unable to cause all or a portion of the revenues of these entities to be distributed.

        All of the domestic surgery centers in which we have ownership interests are limited partnerships, limited liability partnerships or limited liability companies in which we own, directly or indirectly, general partnership or managing member interests. Our limited partnership, limited liability partnership and limited liability company agreements, which are typically with the physicians who perform procedures at our surgery centers, usually provide for the quarterly distribution of net revenues from operations, less amounts used for expenses and working capital. We generally control the entities that function as the general partner of the limited partnerships or the managing member of the limited liability companies through which we conduct operations. However, we do not have exclusive control in some instances over the amount of net revenues distributed from some of our operating entities. If we are unable to cause sufficient revenues to be distributed from one or more of these entities, our relationships with the physicians who have an interest in these entities may be damaged and we could be adversely affected. We may not be able to resolve favorably any dispute regarding revenue distribution or other matters with a healthcare system with which we share control of one of these entities. Further, the failure to resolve a dispute with these healthcare systems could cause the entity we jointly control to be dissolved.


Because affiliated stockholders together own a large percentage of our common stock, they are able to exert significant influence over all matters submitted to our stockholders for approval, regardless of the preferences of our other stockholders.

        Our officers, directors and affiliated entities together own approximately 20% of our outstanding common stock. Accordingly, these stockholders are able to exert significant influence over:

        These stockholders are also able to exert significant influence over a change in control of our company or an amendment to our certificate of incorporation or bylaws. Their interests may conflict with the interests of other holders of common stock and they may take actions affecting us with which you disagree.


Provisions of our charter documents, Delaware law and our stockholder rights plan could discourage a takeover you may consider favorable or the removal of our current management.

        Some provisions of our certificate of incorporation and bylaws may discourage, delay or prevent a merger or acquisition that you may consider favorable or the removal of our current management. These provisions:

36


        In addition, our certificate of incorporation prohibits the amendment of many of these provisions in our certificate of incorporation by our stockholders unless the amendment is approved by the holders of at least 80% of our shares of common stock.

        Delaware law may also discourage, delay or prevent someone from acquiring or merging with us. In addition, purchase rights distributed under our stockholder rights plan will cause substantial dilution to any person or group attempting to acquire us without conditioning the offer on our redemption of the rights. As a result, our stock price may decrease and you might not receive a change of control premium over the then-current market price of the common stock.


Item 2. Properties

        The response to this item is included in Item 1.


Item 3. Legal Proceedings

        We have been named as a defendant in a lawsuit filed by former shareholders of Surgicoe Corporation, which we acquired in March 2002. The suit alleges that we failed to discharge certain post-closing obligations under the acquisition agreement. We believe that the suit is wholly without merit, and we intend to vigorously defend the suit. In addition, from time to time, we may be named as a party to legal claims and proceedings in the ordinary course of business. We are not aware of any other claims or proceedings against us or our subsidiaries that might have a material adverse impact on us.


Item 4. Submission of Matters to a Vote of Security Holders

        None.

37




PART II

Item 5. Market for Registrant's Common Equity and Related Stockholder Matters

        Market for Common Stock.    Our common stock has traded on the Nasdaq National Market under the symbol "USPI" since June 8, 2001. As of March 15, 2003, there were approximately 284 record holders of our common stock. The following table sets forth for the periods indicated the high and low sales price per share of our common stock as reported on the Nasdaq National Market.

 
  High
  Low
Year Ended December 31, 2001:            
  Second Quarter   $ 24.00   $ 17.07
  Third Quarter     25.15     18.00
  Fourth Quarter     21.15     15.55

Year Ended December 31, 2002:

 

 

 

 

 

 
  First Quarter   $ 23.20   $ 16.50
  Second Quarter     33.38     22.52
  Third Quarter     32.32     21.15
  Fourth Quarter     24.35     13.65

        We have not declared or paid any dividends on our common stock and do not anticipate doing so in the foreseeable future. We currently intend to retain all future earnings to fund the development and growth of our business. The payment of any future dividends will be at the discretion of our board of directors and will depend on:

        Our credit facilities and the indenture governing the senior subordinated notes of our wholly owned finance subsidiary, United Surgical Partners Holdings, Inc., currently place restrictions on our ability to pay cash dividends on our common stock.

        Recent Sales of Unregistered Securities.    The following information relates to all securities issued or sold by us in 2002, as adjusted to reflect our one for three reverse stock split completed on June 7, 2001, that were not registered under the Securities Act. Each of the transactions described below was conducted in reliance upon the exemptions from registration provided in Section 4(2) of the Securities Act and the rules and regulations promulgated thereunder.

        On June 30, 2002, the Company issued 3,150 shares of common stock to Calvin R. Dyer in connection with his execution of an affiliation agreement with the Company.

        On June 30, 2002, the Company issued 2,812 shares of common stock to Robert A. Fada in connection with his execution of an affiliation agreement with the Company.

        On June 30, 2002, the Company issued 2,974 shares of common stock to Eduardo J. Olmedo in connection with his execution of an affiliation agreement with the Company.

        On June 30, 2002, the Company issued 3,894 shares of common stock to South Atlanta Orthopedic & Hand Surgery, P.C. in connection with its execution of an affiliation agreement with the Company.

38



        On June 30, 2002, the Company issued 1,087 shares of common stock to Jeffrey A. Uzzle in connection with his execution of an affiliation agreement with the Company.

        On August 12, 2002, the Company issued 2,830 shares of common stock to Dale R. Allen in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 1,617 shares of common stock to T. Bradley Benedict in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 2,830 shares of common stock to Joseph M. Berman in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 2,830 shares of common stock to Anthony Brentlinger in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 2,830 shares of common stock to Jeffrey D. Carter in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 2,830 shares of common stock to Jim Hillard in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 1,617 shares of common stock to John W. Landry in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 1,617 shares of common stock to John W. Loudermilk in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 2,830 shares of common stock to Michael L. Mycoskie in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 2,830 shares of common stock to Philip J. Mycoskie in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 862 shares of common stock to Luat T. Nguyen in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 2,830 shares of common stock to Paul Phillips in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 1,617 shares of common stock to James Pyland in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 1,617 shares of common stock to James Pollifrone in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 2,830 shares of common stock to Jay Pond in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On November 30, 2002, the Company issued 539 shares of common stock to Joseph T. Southerland in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 31, 2002, the Company issued 269 shares of common stock to Howard A. Stein in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 862 shares of common stock to Stuart Thomas in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On August 12, 2002, the Company issued 1,617 shares of common stock to William Valentine in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

39



        On August 12, 2002, the Company issued 2,830 shares of common stock to Mark Woolf in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On October 1, 2002, the Company issued 978 shares of common stock to Jon E. Minter in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On October 1, 2002, the Company issued 1,748 shares of common stock to Raymond C. Hui in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On October 1, 2002, the Company issued 1,748 shares of common stock to Michael T. Casey in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On October 1, 2002, the Company issued 2,103 shares of common stock to David B. Hahn in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On October 1, 2002, the Company issued 1,093 shares of common stock to Peter B. Harvey in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.

        On October 1, 2002, the Company issued 862 shares of common stock to Michael A. Milek in connection with the Company's acquisition of an interest in Arlington Surgicare Partners, Ltd.


Item 6. Selected Consolidated Financial Data

        The selected consolidated statement of operations data set forth below for the period from February 27, 1998 (inception) through December 31, 1998 and the years ended December 31, 1999, 2000, 2001 and 2002, and the consolidated balance sheet data at December 31, 1998, 1999, 2000, 2001, and 2002 are derived from our consolidated financial statements, which have been audited by KPMG LLP, independent auditors.

        The historical results presented below are not necessarily indicative of results to be expected for any future period. The comparability of the financial and other data included in the table is affected by our loss on early retirement of debt in 2001, our impairment of investment securities in 2002, our acquisition of OrthoLink on February 12, 2001 and of Aspen Healthcare Holdings Limited on April 6, 2000 as well as other acquisitions completed since our inception. For a more detailed explanation of this financial data, see "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and related notes included elsewhere in this report.

 
  Period from
February 27, 1998
(inception) through
December 31, 1998

  Years Ended December 31,
 
 
  1999
  2000
  2001(a)
  2002
 
 
  (In Thousands, Except Per Share and Facility Data)

 
Consolidated Statement of Operations Data:                                
Total revenues   $ 20,572   $ 70,413   $ 138,408   $ 244,368   $ 342,386  
Operating expenses excluding depreciation and amortization     22,788     65,635     116,621     184,478     244,827  
Depreciation and amortization     2,015     7,875     14,138     26,116     26,530  
   
 
 
 
 
 
Operating income (loss)     (4,231 )   (3,097 )   7,649     33,774     71,029  
Other income (expense):                                
  Interest income     722     329     912     852     792  
  Interest expense     (497 )   (3,145 )   (12,540 )   (18,120 )   (25,721 )
  Loss on early retirement of debt                 (7,466 )    
  Impairment of investment securities                     (1,057 )
  Other     (246 )   (362 )   (782 )   146     (151 )
   
 
 
 
 
 
Income (loss) before minority interest     (4,252 )   (6,275 )   (4,761 )   9,186     44,892  
Minority interest in (income) loss of consolidated subsidiaries     23     (118 )   (2,332 )   (7,558 )   (14,846 )
Income tax (expense) benefit     301     (451 )   (1,070 )   1,122     (10,446 )
   
 
 
 
 
 
Net income (loss)     (3,928 )   (6,844 )   (8,163 )   2,750     19,600  

40


Net income (loss) attributable to common stockholders(b)   $ (4,356 ) $ (8,540 ) $ (14,134 ) $ 66   $ 19,600  
Share Data:                                
Net income (loss) attributable to common stockholders:                                
  Basic earnings (loss) per share:   $ (1.29 ) $ (1.17 ) $ (1.80 )     $ 0.79  
  Diluted earnings (loss) per share:   $ (1.29 ) $ (1.17 ) $ (1.80 )     $ 0.75  
Weighted average number of common shares:                                
  Basic     3,366     7,308     7,850     18,380     24,925  
  Diluted     3,366     7,308     7,850     19,291     26,056  
Other Data:                                
Number of facilities operated as of the end of period     16     28     33     49     64  
EBITDA(c)   $ (2,216 ) $ 4,778   $ 21,787   $ 59,890   $ 97,559  
EBITDA less minority interests(c)     (2,193 )   4,660     19,455     52,332     82,713  
Cash flows from operating activities     621     4,190     11,002     40,857     59,205  

41


 
  As of December 31,

 

 

1998


 

1999


 

2000


 

2001


 

2002

 
  (Dollars in Thousands)

Consolidated Balance Sheet Data:                              
Working capital   $ 18,490   $ 10,461   $ (58,213 ) $ 40,285   $ 51,412
Cash and cash equivalents     4,965     3,817     3,451     33,881     47,571
Total assets     124,792     176,703     330,396     556,857     727,285
Total debt     11,675     72,684     187,767     238,681     276,703
Redeemable preferred stock     34,344     36,040     32,819        
Total stockholders' equity     52,103     36,571     48,797     226,527     322,261

(a)
Reflects the reclassification of a $7.5 million loss on early extinguishment of debt from extraordinary items to other expense and provision for income taxes, reflecting our adoption, as of December 31, 2002, of Statement of Financial Accounting Standards No. 145, Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections (SFAS No. 145).

(b)
Includes preferred stock dividends of $428, $1,696, $5,971, $2,684 and $-0- for the period from February 27, 1998 (inception) through December 31, 1998 and the years ended December 31, 1999, 2000, 2001 and 2002, respectively. No common stock dividends were declared or paid in any period.

(c)
EBITDA is calculated as operating income plus depreciation and amortization. EBITDA should not be considered in isolation or as a substitute for net income (loss), operating income (loss), cash flows provided by operating activities or any other measure of operating performance calculated in accordance with generally accepted accounting principles. EBITDA is widely used by financial analysts as a measure of financial performance. Our calculation of EBITDA may not be comparable to similarly titled measures reported by other companies.


Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation

        The following discussion and analysis of our financial condition and results of operations should be read in conjunction with "Selected Consolidated Financial Data" and our consolidated financial statements and related notes included elsewhere in this report.


Overview

        We operate surgery centers and private surgical hospitals in the United States and Western Europe. As of December 31, 2002, we operated 64 facilities, consisting of 54 in the United States, eight in Spain, and two in the United Kingdom. Of the 54 U.S. facilities, 26 are jointly owned with ten major not-for-profit healthcare systems. Overall, as of December 31, 2002, we held ownership interests in 61 of the facilities and operated the remaining three facilities, all in the United States, under management contracts.

        For the year ended December 31, 1999, our first full year in operation, we generated $70.4 million of revenues, a $3.1 million operating loss and $4.7 million of EBITDA less minority interest. For the year ended December 31, 2002, our revenues had grown to $342.4 million, we generated $71.0 million of operating income and our EBITDA less minority interests had grown to $82.7 million.


Critical Accounting Policies

        Our management is required to make certain estimates and assumptions during the preparation of our consolidated financial statements in accordance with generally accepted accounting principles. These estimates and assumptions impact the reported amount of assets and liabilities and disclosures of

42



contingent assets and liabilities as of the date of the consolidated financial statements. They also impact the reported amount of net earnings during any period. Actual results could differ from those estimates. Certain of our accounting policies and estimates have a more significant impact on our financial statements than others, due to the size of the underlying financial statement elements.

        Our determination of the appropriate consolidation method to follow with respect to our investments in subsidiaries and affiliates is based on the amount of control we have, combined with our ownership level, in the underlying entity. Our consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and other subsidiaries over which we have control. Our investments in subsidiaries in which we have the ability to exercise significant influence over operating and financial policies, but do not control (including subsidiaries where we have less than 20% ownership) are accounted for on the equity method. All of our other investments are accounted for on the cost method.

        Accounting for an investment as either consolidated versus equity method generally has no impact on our net income or stockholders' equity in any accounting period, but does impact individual income statement and balance sheet balances, as consolidation effectively grosses up our income statement and balance sheet. However, if control or influence aspects of an equity method investment were different, it could result in us being required to account for an investment by consolidation or using the cost method. Under the cost method, the investor only records its share of the underlying entity's earnings to the extent that it received dividends or distributions from the investee. Under the cost method, the investor does not record its share of income or losses of the investee. Conversely, under either consolidation or equity method accounting, the investor effectively records its share of the underlying entity's net income or loss based on its ownership percentage. At December 31, 2002, $0.3 million of the Company's total investment in unconsolidated affiliates of $18.7 million relates to investments that are accounted for using the cost method and the remaining $18.4 million represents investments in unconsolidated affiliates accounted for using the equity method.

        We recognize revenue in accordance with Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements, which has four basic criteria that must be met before revenue is recognized:

Our revenue recognition policies are consistent with these criteria. Our revenues that are subject to the most judgment are those patient service revenues that are not generated under contracted or government mandated fee schedules or discount arrangements. Approximately 14% of our net revenues for the year ended December 31, 2002 were generated by noncontracted and nongovernment payors. The allowances that we record for these revenues are based on our best estimates of expected actual reimbursement based primarily on historical collections for similar transactions.

        Management accounts for income taxes under the asset and liability method. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets

43


is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. If, in the opinion of management, it is more likely than not that some or all of the deferred tax assets may not be realized, deferred tax assets are reduced by a valuation allowance.

        Beginning January 1, 2002, we also consider our accounting policy regarding intangible assets to be a critical accounting policy given the significance of intangible assets as compared to our total assets and the recent changes in accounting for intangible assets required under Statement of Financial Accounting Standards No. 142, Accounting for Goodwill and Other Intangible Assets (SFAS No. 142), which was issued by the Financial Accounting Standards Board on July 20, 2001 and was adopted by us as of January 1, 2002. SFAS No. 142 requires the cessation of amortization of goodwill and identifiable intangible assets which do not have finite lives and requires that all intangible assets be tested for impairment at least annually. We adopted this standard on January 1, 2002, which did not result in impairment in any of our reporting units, which we determined to be at our operating segment (country) level.


Acquisitions, Equity Investments and Development Projects

        In March 2003, we acquired a surgical hospital in Marbella, Spain, for approximately $9.2 million in cash. In addition, we agreed to pay up to an additional total of $4.8 million to the sellers, depending on the resolution of certain contingencies over the next four years.

        During 2002, four surgery centers and two private surgical hospitals developed by us in the United States opened and began performing cases.

        In December 2002, we acquired an additional 29% of a surgery center in Torrance, California, in which we had previously been a minority owner, for $9.3 million in cash, bringing our total ownership in the facility to 63% and triggering our consolidation of the facility in our financial statements.

        In October 2002, we acquired an 80% interest in a surgery center in Lyndhurst, Ohio, for $8.1 million in cash.

        In August 2002, with an effective date of July 1, 2002, we acquired an additional 35% interest in a surgery center in Arlington, Texas (Arlington) for total consideration of $8.0 million, consisting of $6.9 million in cash and $1.1 million of our common stock, bringing our total ownership interest in the center to 45%. Because we own a majority of a subsidiary that owns a majority of the surgery center and maintains effective control through this ownership interest and through our operation of the center pursuant to a management contract, we consolidated the results of Arlington's operations in our financial statements.

        In June 2002, we acquired a 57% interest in a surgery center in Middleburg Heights, Ohio, a suburb of Cleveland, for $2.1 million in cash.

        In May 2002, we acquired a 67% interest in a surgery center in Corpus Christi, Texas for $10.8 million in cash.

        In March 2002, we acquired SURGICOE Corporation, which owns, manages, and develops surgical facilities in Georgia, Oklahoma, and Texas. We paid the shareholders of SURGICOE approximately $5.3 million in cash. The terms of the agreement provide for us to make additional payments in the future should certain facilities, including some that are operational and some that are currently under development, meet specified performance targets.

        In February 2002, we acquired a surgical hospital in Murcia, Spain, for total consideration of approximately $8.2 million in cash (of which $7.5 million was paid upon the consummation of the

44



acquisition and $0.7 million will be paid on the first anniversary of the consummation of the acquisition) and approximately $12.6 million in assumed capital lease obligations.

        We also engage in investing transactions that are not business combinations, consisting primarily of purchases and sales of noncontrolling equity interests in surgical facilities and the investment of additional cash in surgical facilities under development. During the year ended December 31, 2002, these transactions resulted in net cash outflows of $12.4 million. The most notable transactions were acquisitions of noncontrolling interests in surgery centers in the following markets: Austintown, Ohio, the first of three centers we began operating in northern Ohio in 2002; Destin, Florida, which is our third center in Florida; East Brunswick, New Jersey, through a newly formed joint venture with Robert Wood Johnson University Hospital; and Atlanta, Georgia, where we increased our existing ownership in one of the six facilities we operate in Georgia.

        During the fourth quarter of 2001, we acquired ownership interests in four surgery centers through separate transactions, expanding to three additional markets in the U.S. In October 2001, we acquired a 66% interest in a surgical facility in Sarasota, Florida for a total consideration of approximately $3.4 million in cash and approximately $1.3 million in assumed debt. During November 2001, we completed two acquisitions:(1) an 80% interest in a surgical facility in West Covina, California (Los Angeles area) for a total consideration of approximately $10.8 million in cash and approximately $1.2 million in assumed debt and (2) an 83% interest in a surgical facility in Fredericksburg, Virginia, for a total consideration of approximately $6.3 million in cash, a warrant to acquire 25,000 shares of our common stock at a price equal to approximately $16.45 per share and approximately $700,000 in assumed debt. In December 2001, we expanded our presence in the Los Angeles area by acquiring a 35% interest in a surgical facility in Torrance, California for a total consideration of approximately $11.0 million.

        During July 2001, we acquired a controlling interest in a surgery center in Fort Worth, Texas for approximately $14.0 million in cash. We had previously operated this surgery center under a management contract. In addition, in July and August 2001, we opened newly developed surgery centers in Knoxville, Tennessee, and Lawrenceville, Georgia.

        On February 12, 2001, we completed a merger with OrthoLink. The transaction was funded through the issuance of 3,367,651 shares of our common stock to OrthoLink stockholders. OrthoLink was incorporated in 1996 and, as of February 1, 2001, held a direct or indirect ownership interest in eight surgery centers. We also held an ownership interest in and managed one of these centers. OrthoLink managed six of the eight surgery centers in which it held an ownership interest and managed two additional surgery centers in which it had no ownership interest. In addition, OrthoLink has service agreements with 14 physician groups in six states. OrthoLink's physician practice management operations are not, and are not expected to be in the future, a material part of our business.

        In April 2000, we acquired 100% of the outstanding common stock of Aspen Healthcare Holdings Limited that owns and operates two private surgical hospitals in England. We paid approximately $89.2 million in cash for that acquisition, approximately $54.0 million of which we borrowed under a credit agreement denominated in British pounds with a commercial lender. Additionally, during 2000, we acquired two hospitals and a radiology center in Madrid, Spain through three separate transactions. We paid approximately $32.2 million for these three acquisitions. Also, during 2000, we opened two newly developed surgery centers in the United States.

45



Sources of Revenue

        Revenues primarily include:

        The following table summarizes our revenues by type and as a percentage of total revenue for the periods indicated (dollars in thousands):

 
  Years Ended December 31,
 
 
  2000
  2001
  2002
 
Net patient service revenue   96 % 86 % 87 %
Management and administrative services revenue   2   11   9  
Equity in earnings of unconsolidated affiliates   1   2   3  
Other income   1   1   1  
   
 
 
 
Total revenue   100 % 100 % 100 %

        The percentage of our total revenues attributable to management and administrative services decreased to 9% for the year ended December 31, 2002 from 11% for 2001 primarily as a result of the additional net patient service revenue resulting from our acquiring controlling interests in surgical facilities during 2001 and 2002. This percentage had increased to 11% for the year ended December 31, 2001 from 2% for 2000 primarily as a result of the additional management and administrative services associated with managing unconsolidated facilities and service agreements added by the acquisition of OrthoLink in February 2001. Our management and administrative services revenues are earned from the following types of activities:

 
  Year ended December 31,
 
  2000
  2001
  2002
Management of surgical facilities   $ 2,158   $ 5,594   $ 9,556
Consulting and other services provided to physicians and related entities         20,555     21,682
   
 
 
  Total management and administrative service revenues   $ 2,158   $ 26,149   $ 31,238

        The majority of our management and administrative services revenue earned from providing services to physicians and related entities resulted from our acquisition of OrthoLink Physicians

46



Corporation (OrthoLink) February 12, 2001. Our results for the year ended December 30, 2001 include only ten and one-half months of OrthoLink operations.

        The following table reflects the summarized results of the unconsolidated facilities that we account for under the equity method of accounting (dollars in thousands):

 
  Year ended December 31,
 
 
  2000
  2001
  2002
 
Total revenues   $ 33,387   $ 84,278   $ 141,166  
Depreciation and amortization     2,730     4,552     7,189  
Operating income     3,669     23,733     41,913  
Interest expense, net     1,059     1,974     4,077  
Net income     2,656     21,371     37,279  
Long-term debt     11,780     27,264     66,596  

USPI's equity in earnings of unconsolidated affiliates

 

 

844

 

 

5,879

 

 

9,454

 
USPI's implied weighted average ownership percentage based on affiliates' net income(1)     31.8 %   27.5 %   25.4 %
USPI's implied weighted average ownership percentage based on affiliates' debt(2)     32.5 %   23.2 %   25.6 %
Unconsolidated facilities operated at period end     9     17     26  

(1)
Our weighted average percentage ownership in our unconsolidated affiliates calculated based on USPI's equity in earnings of unconsolidated affiliates divided by the total net income of the affiliates for each respective year.
(2)
Our weighted average percentage ownership in our unconsolidated affiliates calculated based on the total debt of each affiliate multiplied by the percentage ownership USPI held in the affiliate as of the end of each respective year.

        For the year ended December 31, 2002, approximately 60% of our revenues were generated from operations in the United Stated and 40% from Western Europe. For 2001 and 2000, these percentages were 55% and 39% for the United States and 45% and 61% for Western Europe, respectively. The increase in the percentage of our revenues generated in the United States and corresponding decrease in Western Europe resulted from focusing our development and acquisition activities primarily in the United States during 2001 and 2002.

47




Results of Operations

        The following table summarizes certain statements of operations items expressed as a percentage of revenues for the periods indicated:

 
  Years Ended December 31,
 
 
  1999
  2000
  2001
  2002
 
Total revenues   100.0 % 100.0 % 100.0 % 100.0 %
Operating expenses, excluding depreciation and amortization   93.2   84.3   75.5   71.5  
   
 
 
 
 
EBITDA   6.8   15.7   24.5   28.5  
Minority interest in income of consolidated subsidiaries   0.2   1.7   3.1   4.3  
Depreciation and amortization   11.2   10.2   10.7   7.7  
Interest and other expense, net   4.5   9.0   10.0 (a) 7.7  
   
 
 
 
 
Income (loss) before income taxes   (9.1 ) (5.2 ) 0.7   8.8  
Income tax (expense) benefit   (0.6 ) (0.7 ) 0.4   (3.1 )
   
 
 
 
 
Net income (loss)   (9.7 )% (5.9 )% 1.1 % 5.7 %
   
 
 
 
 

(a)
Reflects a reclassification of a loss on early retirement of debt that was classified as an extraordinary item in 2001, but has been reclassified to interest and other expense, net in this presentation, reflecting our adoption of SFAS No. 145.


Year Ended December 31, 2002 Compared to Year Ended December 31, 2001

        Revenues increased by $98.0 million, or 40%, to $342.4 million for the year ended December 31, 2002 from $244.4 million for the year ended December 31, 2001. Of this increase, $52.8 million was contributed by facilities acquired or opened since December 31, 2000. The U.S. dollar was weaker relative to the Eurodollar and the British pound during the year ended December 31, 2002 as compared to the same period in the prior year, resulting in a positive impact of $6.1 million on year over year revenues for the facilities in Western Europe that we owned in both 2002 and 2001 ("same store" facilities). Absent this foreign exchange impact, same store facilities in Western Europe contributed $11.6 million more to consolidated revenue in the year ended December 31, 2002 as compared to the same period in 2001. The remaining increase in revenues was contributed principally by same store U.S. facilities, which performed approximately 17% more cases during the year ended December 31, 2002 as compared to the year ended December 31, 2001.

        Operating expenses, excluding depreciation and amortization, increased by $60.3 million, or 33%, to $244.8 million for the year ended December 31, 2002 from $184.5 million for the year ended December 31, 2001. Operating expenses, excluding depreciation and amortization, as a percentage of revenues, decreased to 71.5% from 75.5%, primarily as a result of increasing revenue base, operating efficiencies at our facilities and improved economies of scale as we expanded.

        EBITDA less minority interest increased $30.4 million, or 58%, to $82.7 million for the year ended December 31, 2002 from $52.3 million for the year ended December 31, 2001. Of this increase in EBITDA less minority interest, $14.9 million was contributed by facilities acquired or opened since December 31, 2000. EBITDA less minority interest, as a percentage of revenues, increased to 24.2% for the year ended December 31, 2002 from 21.4% for the year ended December 31, 2001, primarily as a result of improved operating margins at our facilities and the leveraging of our corporate overhead expenses over the increased revenue.

        Depreciation and amortization increased $0.4 million, or 2%, to $26.5 million for the year ended December 31, 2002 from $26.1 million for the year ended December 31, 2001. This amount remained virtually constant because the reduction in expense resulting from the cessation of goodwill

48



amortization required under SFAS No. 142 largely offset the additional depreciation on tangible assets acquired through acquisitions. Depreciation and amortization as a percentage of revenues decreased to 7.7% for the year ended December 31, 2002 from 10.7% for the year ended December 31, 2001 due to our increased revenue.

        Interest expense, net of interest income, increased $7.6 million, or 44%, to $24.9 million for the year ended December 31, 2002 from $17.3 million for the year ended December 31, 2001, primarily as a result of higher levels of outstanding debt during the year ended December 31, 2002 than during the prior year period. We used a portion of the proceeds of our two public offerings of common stock to repay senior and subordinated indebtedness in June 2001 and have incurred debt to fund a portion of our acquisition and development program since that time.

        Other expense, net of other income decreased $6.1 million, or 83%, to $1.2 million for the year ended December 31, 2002 from $7.3 million for the year ended December 31, 2001, primarily due to the $7.5 million loss on early retirement of debt recorded in 2001 being so much larger than the $1.1 million impairment of investment securities recorded in 2002.

        Provision for income taxes was a net expense of $10.4 million, representing an effective tax rate of 35%, for the year ended December 31, 2002, compared to a net benefit of $1.1 million, representing a negative effective tax rate of 69%, for the year ended December 31, 2001. The increase in our actual provision for income taxes and in our overall effective tax rate primarily results from our accruing no net federal tax expense related to U.S. operations prior to January 1, 2002, at which time we began accruing taxes at rates approximating statutory rates. We utilized net operating loss carryforwards (NOLs) to offset current period income as our U.S. operations achieved profitability for the first time during 2001, and during the fourth quarter of 2001 we fully recognized the benefit of all U.S. NOLs generated during our initial years of operations.

        Net income was $19.6 million for the year ended December 31, 2002 compared to $2.8 million for the year ended December 31, 2001. This $16.8 million improvement results primarily from the increased revenues and improved economies of scale related to expenses discussed above.


Year Ended December 31, 2001 Compared to Year Ended December 31, 2000

        Revenues increased by $106.0 million, or 77%, to $244.4 million for the year ended December 31, 2001 from $138.4 million for the year ended December 31, 2000. Of this increase in revenues, $59.0 million was contributed by facilities acquired since December 31, 2000, of which $48.1 million was contributed by OrthoLink. An additional $10.2 million was attributable to revenue generated in the first quarter of fiscal 2001 by the two hospitals in the United Kingdom. These hospitals were acquired on April 6, 2000. The exchange rates of the European currencies to the U.S. dollar were lower during the year ended December 31, 2001 as compared to the prior year, resulting in a negative impact of $2.5 million on year over year revenues for the facilities in Western Europe that were owned in both 2001 and 2000 ("same store" facilities). Absent this foreign exchange impact, same store facilities in Western Europe contributed $9.3 million more to consolidated revenue in the year ended December 31, 2001 as compared to 2000. The remaining increase in revenues was contributed by same store U.S. facilities, which performed approximately 18% more cases in the year ended December 31, 2001 as compared to 2000.

        Operating expenses, excluding depreciation and amortization, increased by $67.9 million, or 58%, to $184.5 million for the year ended December 31, 2001 from $116.6 million for 2000. Operating expenses, excluding depreciation and amortization, as a percentage of revenues, decreased to 75.5% for the year ended December 31, 2001 from 84.3% for 2000, primarily as a result of improved economies of scale as we expanded.

49



        EBITDA less minority interest increased $32.9 million, or 169%, to $52.3 million for the year ended December 31, 2001 from $19.5 million for 2000. Of this increase in EBITDA less minority interest, $20.4 million was contributed by facilities acquired since December 31, 2000. EBITDA less minority interest, as a percentage of revenues, increased to 21.4% for the year ended December 31, 2001 from 14.1% for 2000, primarily as a result of an improvement of operating margins at our facilities operated in joint ventures with healthcare systems and the leveraging of our corporate overhead expenses over the increased revenue.

        Depreciation and amortization increased $12.0 million, or 85%, to $26.1 million for the year ended December 31, 2001 from $14.1 million for 2000 as a result of amortization of the goodwill and other intangibles and depreciation of the additional property and equipment associated with the acquisitions completed during 2000 and 2001. Depreciation and amortization, as a percentage of revenues, increased to 10.7% for the year ended December 31, 2001 from 10.2% for 2000, primarily as a result of the amortization of management contracts and other intangibles associated with the OrthoLink acquisition. In accordance with a preadoption requirement of SFAS No. 142, we did not amortize goodwill resulting from acquisitions consumated after June 30, 2001.

        Interest expense, net of interest income, increased 49% to $17.3 million for the year ended December 31, 2001 from $11.6 million for 2000, primarily as a result of the debt assumed in connection with the OrthoLink acquisition and additional borrowings to finance other acquisitions during 2000 and 2001.

        Other expense, net of other income, increased $6.5 million to $7.3 million for the year ended December 31, 2001 from $0.8 million for 2001, primarily as a result of our recording a $7.5 million loss on early retirement of debt in 2001, as a result of the early termination of our credit facility in Spain and the retirement of the Senior Subordinated Notes of USP Domestic Holdings, Inc., one of our wholly-owned subsidiaries, using the proceeds of our $150 million senior subordinated debt offering. The items included in the loss consisted primarily of unamortized debt issuance costs of the Spain credit facility and unamortized discount related to the Senior Subordinated Notes.

        Provision for income taxes was a benefit of $1.1 million for the year ended December 31, 2001 and expense of $1.1 million for 2000. Our tax provision for both years consists primarily of taxes on income generated in the U.K., Spanish taxes on the income of entities that were not eligible for inclusion in the consolidated tax group in that country and state income taxes in the U.S. As of December 31, 2001, the benefit of essentially all U.S. net operating losses that were not subject to significant change in control limitations have been recognized in our financial statements, resulting in a net tax benefit for 2001, and we expect our effective tax rate in future periods will more closely approximate statutory rates.

        Net income was $2.7 million for the year December 31, 2001 as compared to a net loss of $8.2 million for 2000. This $10.9 million improvement primarily results from the increased revenues and improved economies of scale related to expenses discussed above.


Liquidity and Capital Resources

        During November 2002, we entered into a second amended and restated credit facility with a group of commercial lenders providing us with the ability to borrow up to $115.0 million for acquisitions and general corporate purposes in the United States and Spain or for any new subsidiary that becomes a guarantor of the facility. A total of $15.0 million of borrowings under the facility may be used by subsidiaries that are not guarantors, including subsidiaries in the United Kingdom. Borrowings under our second amended and restated credit facility mature on November 7, 2005. As of December 31, 2002, no amounts were outstanding under this facility and $39.0 million was available for borrowing based on actual reported consolidated financial results. Maximum availability under the facility is based upon pro forma EBITDA including EBITDA from acquired entities. Assuming

50



historical purchase multiples of annual EBITDA of potential acquisition targets, approximately $84.0 million would be available for borrowing to finance acquisitions as of December 31, 2002, of which none was drawn at December 31, 2002. Our second amended and restated credit facility agreement and the indenture governing our Senior Subordinated Notes contain various restrictive covenants including covenants that limit our ability and the ability of certain of our subsidiaries to borrow money or guarantee other indebtedness, grant liens on our assets, make investments, use assets as security in other transactions, pay dividends on stock, enter into sale and leaseback transactions or sell assets or capital stock.

        In October 2002, we received, after offering costs of approximately $4.0 million, net proceeds of approximately $49.1 million from an offering of 2.415 million shares of our common stock, which included 315,000 shares attributable to the underwriters' exercise of their over-allotment option. Net proceeds were used as follows:

        During the year ended December 31, 2002, we generated $59.2 million of cash flows from operations as compared to $40.9 million during 2001 and $11.0 million during 2000. During the year ended December 31, 2002, our net cash required for investing activities was $91.5 million, consisting primarily of $62.4 million for the purchase of businesses and $30.1 million for the purchase of property and equipment. The $62.4 million primarily represents purchases of new businesses, net of cash received, and incremental investments in unconsolidated affiliates. The most significant of these transactions were the $10.8 million paid for the surgery center in Corpus Christi, Texas, the $8.1 million paid to acquire the surgery center in Lyndhurst, Ohio, the $9.3 million paid to acquire the additional interest in the surgery center in Torrance, California, the $7.5 million paid for the surgical hospital in Murcia, Spain, the $6.9 million paid to acquire the additional interest in the surgery center in Arlington, Texas, and the $5.3 million paid to acquire Surgicoe. Approximately $12.0 million of the property and equipment purchases related to ongoing development projects, and the remaining $18.1 million primarily represents purchases of equipment at existing facilities. The $91.5 million of cash required for investing activities was funded with the cash flows from operations noted above and borrowings under our credit facilities, which were subsequently repaid with the proceeds from our stock offering. Net cash provided during the year ended December 31, 2002 by financing activities totaled $45.4 million and resulted primarily from proceeds of a stock offering. Cash and cash equivalents were $47.6 million at December 31, 2002 as compared to $33.9 million at December 31, 2001 and net working capital was $51.4 million at December 31, 2002 as compared to $40.3 million in the prior year.

        The credit agreement in the United Kingdom provides for total borrowings of £42.0 million (approximately $67.6 million as of December 31, 2002) under three separate facilities. At December 31, 2002, total outstanding borrowings under this credit agreement were approximately $53.7 million and approximately $3.0 million was available for borrowings.. Borrowings under the United Kingdom credit facility bear interest at rates of 1.50% to 2.00% over LIBOR and mature in April 2010. We pledged the capital stock of our U.K. subsidiaries to secure borrowings under the United Kingdom credit facility. We were in compliance with all covenants under our credit agreements as of December 31, 2002.

51



        Our obligations under debt and lease contracts as of December 31, 2002 may be summarized as follows:

 
  Payments Due by Period (In Thousands)
Contractual Cash Obligations

  Total
  Within 1 year
  1 to 3 years
  4 to 5 years
  Beyond 5 years
Long term debt:                              
  Senior Subordinated Notes   $ 148,910   $   $   $   $ 148,910
  U.S. Credit Facility                    
  U.K. Credit Facility     53,724     2,414     6,745     10,784     33,781
  Loans from former owners of subsidiaries     1,719     832     876     11    
  Other Debt at operating subsidiaries     7,332     2,557     3,564     1,191     20
Capitalized lease obligations:                              
  U.S. operating subsidiaries     29,018     6,151     8,914     2,006     11,947
  Western Europe operating subsidiaries     36,000     1,178     1,895     1,144     31,783
Operating lease obligations:                              
  U.S. operating subsidiaries     51,540     6,445     11,913     10,801     22,381
  Western Europe operating subsidiaries     8,495     1,245     1,841     1,576     3,833
   
 
 
 
 
Total contractual cash obligations   $ 336,738   $ 20,822   $ 35,748   $ 27,513   $ 252,655
   
 
 
 
 

        Our operating subsidiaries, many of which have minority owners who share in the cash flow of these entities, have debt consisting primarily of capitalized lease obligations. This debt is generally non-recourse to USPI, the parent company, and is generally secured by the assets of those operating entities. The total amount of these obligations, which was $74.8 million at December 31, 2002, is included in our consolidated balance sheet because the borrower or obligated entity meets the requirements for consolidated financial reporting. Our average percentage ownership, weighted based on the individual subsidiary's amount of debt and capitalized leased obligations, of these consolidated subsidiaries was 84.5% at December 31, 2002. Additionally, our unconsolidated affiliates that we account for under the equity method have debt and capitalized lease obligations that are generally non-recourse to USPI and are not included in our consolidated financial statements. At December 31, 2002, the total obligations of these unconsolidated affiliates under debt and capital lease obligations was approximately $66.6 million. Our average percentage ownership, weighted based on the individual affiliate's amount of debt and capitalized lease obligations, of these unconsolidated affiliates was 25.6% at December 31, 2002. USPI or one of its wholly owned subsidiaries had collectively guaranteed $9.0 million of the $66.6 million in total debt and capital lease obligations of our unconsolidated affiliates as of December 31, 2002.

        These unconsolidated affiliates are limited partnerships, limited liability partnerships or limited liability companies that own operational surgical facilities or surgical facilities that are under development. None of these affiliates provide financing, liquidity, or market or credit risk support for us. They also do not engage in leasing, hedging, research and development services with us. Moreover, we do not believe that they expose us to any of their liabilities that are not otherwise reflected in our consolidated financial statements. We are not obligated to fund losses or otherwise provide additional funding to these affiliates other than as we determine to be economically required in order to successfully implement our development plans.

        Currently, USPI and its affiliates have one surgery center and one private surgical hospital under construction and two additional surgery centers in the planning stage in the United States. A typical surgery center costs from $5.0 to $6.0 million to develop, including construction, equipment and initial

52



operating losses. These costs vary depending on the range of specialties that will be undertaken at the facility. Our affiliates have budgeted an average of $4.8 million for development costs for each of the three surgery center projects and approximately $21.5 million for the surgical hospital project. For the surgical facilities where construction has begun, equity contributions have been made, including those required of USPI, and external financing has been put in place at the unconsolidated affiliate and no additional financing needs are anticipated. Development costs are typically funded with approximately 50% debt at the entity level with the remainder provided as equity from the owners of the entity.

        In addition to the current development projects in the United States, our Parkside Hospital in London is developing a cancer treatment center that is expected to become operational during the second quarter of 2003. The remaining costs of this project are estimated to be approximately £4.0 ($6.4 million), which we anticipate funding with borrowings under our credit facilities and cash flows from operations.

        Our acquisition and development program will require substantial capital resources, which we estimate to range from $35.0 million to $50.0 million per year over the next three years, including an estimated $3.5 million related to additional consideration to the sellers of acquired facilities based upon those facilities achieving certain financial targets. In addition, the operations of our existing surgical facilities will require ongoing capital expenditures. We believe that existing funds, cash flows from operations and borrowings under our credit facilities will provide sufficient liquidity for the next twelve months. Thereafter, it is likely that we will require additional debt or equity financing for our acquisitions and development projects. There are no assurances that needed capital will be available on acceptable terms, if at all. If we are unable to obtain funds when needed or on acceptable terms, we will be required to curtail our acquisition and development program.


New Accounting Pronouncements

        In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities. This standard requires that a liability for costs associated with an exit or disposal activity be recognized when the liability is incurred. Under previous accounting standards, a liability for an exit cost (as defined by the standard) was recognized at the date of an entity's commitment to an exit plan. The provisions of SFAS No. 146 are effective for exit or disposal activities initiated after December 31, 2002. To the extent that we initiate exit or disposal activities after this date, SFAS No. 146 might have a material effect on our results of operations or financial position.

        In November 2002, the FASB issued Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness to Others (FIN 45). FIN 45 addresses financial accounting for and disclosure of guarantees, requiring certain guarantees issued or modified after December 31, 2002 to be recorded at fair value. This treatment differs from the existing treatment, under SFAS No. 5, Accounting for Contingencies, of recording a liability only when a loss is probable and reasonably estimable. We adopted the disclosure requirements, which apply to existing guarantees as well as newly issued ones, as of December 31, 2002. The portion of the standard requiring certain guarantees to be recorded at fair value was adopted January 1, 2003, and is not expected to have a material impact on our financial position and results of operations.

        In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation—Transition and Disclosure. This new standard amends SFAS No. 123, Accounting for Stock-Based Compensation, to provide for alternative methods of transition for an entity that voluntarily changes to the fair value based method of accounting for stock-based employee compensation. In addition, the standard amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial statements. Certain of the disclosure modifications are required for fiscal years ending after December 15, 2002 and were adopted by us as of December 31, 2002.

53



        In January 2003, the FASB issued Interpretation No. 46, Consolidation of Variable Interest Entities, an Interpretation of ARB No. 51 (FIN 46). FIN 46 addresses the consolidation by business enterprises of variable interest entities, as defined in the Interpretation, and is applicable for years ending after June 15, 2003 to interests in variable interest entities created or obtained after January 31, 2003. We do not expect the application of this standard to have a material impact on our financial position or results of operations.


Item 7A. Quantitative and Qualitative Disclosures about Market Risk

        We have exposure to interest rate risk related to our financing, investing and cash management activities. Historically, we have not held or issued derivative financial instruments other than the use of variable-to-fixed interest rate swaps for portions of our borrowings under credit facilities with commercial lenders as required by the credit agreements. We do not use derivative financial instruments for speculative purposes. Our financing arrangements with commercial lenders are based on a spread over LIBOR or Euribor. At December 31, 2002, $148.9 million of our total outstanding debt was the Senior Subordinated Notes, which were issued in December 2001 at a 0.8% discount and bear interest at a fixed rate of 10%, $2.7 million was in other fixed rate instruments and the remaining $57.0 million was in variable rate instruments. Accordingly, a hypothetical 100 basis point increase in market interest rates would result in additional annual interest expense of $0.6 million. The Senior Subordinated Notes, which represent 98% of our total fixed rate debt at December 31, 2002 are considered to have a fair value, based upon recent trading, of $155.4 million, which is approximately $6.5 million higher than the carrying value at December 31, 2002.

        Our international revenues are a growing portion of our total revenues. We are exposed to risks associated with operating internationally, including:

        Our international operations operate in a natural hedge to a large extent because all operating expenses and revenues are denominated in local currency. Additionally, our borrowings in the United Kingdom are currently denominated in local currency. Historically, the cash flow generated from our operations in Spain and the United Kingdom have been utilized within each of those countries to finance development and acquisition activity as well as for repayment of debt denominated in local currency. Accordingly, we have not utilized financial instruments to hedge our foreign currency exchange risk.

        Inflation and changing prices have not significantly affected our operating results or the markets in which we perform services.


Item 8. Financial Statements and Supplementary Data

        For the financial statements and supplementary data required by this Item 8, see the Index to Consolidated Financial Statements included elsewhere in this Form 10-K.


Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

        None.


PART III

Item 10. Directors and Executive Officers of the Registrant

        The response to this item will be included in the Company's Proxy Statement for its Annual Meeting of Stockholders to be held in 2003 and is incorporated herein by reference.

54




Item 11. Executive Compensation

        The response to this item will be included in the Company's Proxy Statement for its Annual Meeting of Stockholders to be held in 2003 and is incorporated herein by reference.


Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

        The response to this item will be included in the Company's Proxy Statement for its Annual Meeting of Stockholders to be held in 2003 and is incorporated herein by reference.


Item 13. Certain Relationships and Related Transactions

        The response to this item will be included in the Company's Proxy Statement for its Annual Meeting of Stockholders to be held in 2003 and is incorporated herein by reference.


Item 14. Controls and Procedures

        The Chairman and Chief Executive Officer and Chief Financial Officer of the Company (its principal executive officer and principal financial officer, respectively) have evaluated the Company's disclosure controls and procedures (as defined in Exchange Act Rules 13a-14(c) and 15d-14(c)) as of a date within 90 days of the filing date of this Annual Report on Form 10-K. Based upon that evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that the Company's disclosure controls and procedures are effective in timely alerting them to material information required to be included in the Company's periodic SEC filings. There were no significant changes in the Company's internal controls, or in other factors that could significantly affect these controls, subsequent to the date of such evaluation.


Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K

(a)    1.    Financial Statements

        The following financial statements are filed as part of this Form 10-K:

Independent Auditors' Report of KPMG LLP   F-1
Consolidated Balance Sheets as of December 31, 2002 and 2001   F-2
Consolidated Statements of Operations for the years ended December 31, 2002, 2001 and 2000   F-4
Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2002, 2001 and 2000   F-5
Consolidated Statements of Stockholders' Equity for the years ended December 31, 2002, 2001 and 2000   F-6
Consolidated Statements of Cash Flows for the years ended December 31, 2002, 2001 and 2000   F-7
Notes to Consolidated Financial Statements   F-8

55


Independent Auditors' Report

The Board of Directors
United Surgical Partners International, Inc.:

We have audited the accompanying consolidated balance sheets of United Surgical Partners International, Inc. and subsidiaries as of December 31, 2002 and 2001, and the related consolidated statements of operations, comprehensive income (loss), stockholders' equity and cash flows for each of the years in the three year period ended December 31, 2002. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of United Surgical Partners International, Inc. and subsidiaries as of December 31, 2002 and 2001, and the results of their operations and their cash flows for each of the years in the three year period ended December 31, 2002, in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 6 to the consolidated financial statements, United Surgical Partners International, Inc. and subsidiaries fully adopted the provisions of Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets" in 2002.

Dallas, Texas
February 19, 2003

F-1


UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Consolidated Balance Sheets

(in thousands, except per share amounts)

December 31, 2002 and 2001

 
  2002
  2001
Assets

   
Cash and cash equivalents   $ 47,571   $ 33,881
Patient receivables, net of allowance for doubtful accounts of $7,154 and $4,726, respectively     39,176     27,546
Other receivables (note 4)     34,735     30,579
Inventories of supplies     7,756     5,685
Deferred tax asset, net     5,657     6,571
Prepaids and other current assets     7,001     6,191
   
 
  Total current assets     141,896     110,453
Property and equipment, net (note 5)     270,387     211,601
Investments in affiliates (note 3)     18,696     12,328
Intangible assets, net (note 6)     287,584     215,809
Other assets     8,722     6,666
   
 
  Total assets   $ 727,285   $ 556,857
   
 
Liabilities and Stockholders' Equity      
Accounts payable   $ 25,989   $ 20,633
Accrued salaries and benefits     20,322     13,760
Due to affiliates     6,890     5,513
Accrued interest     1,650     1,822
Current portion of long-term debt (note 8)     13,132     10,640
Other accrued expenses     22,501     17,007
Deferred tax liability, net         793
   
 
  Total current liabilities     90,484     70,168
   
 
Long-term debt, less current portion (note 8)     263,571     228,041
Other long-term liabilities     4,532     3,130
Deferred tax liability, net     19,577     12,916
   
 
  Total liabilities     378,164     314,255
Minority interests (note 3)     26,860     16,075
Commitments and contingencies (notes 9 and 17)            

(Continued)

F-2


 
  2002
  2001
 
Stockholders' equity (notes 10 and 11):              
  Common stock              
    Other, $0.01 par value; 200,000 shares authorized; 27,306 and 24,436 shares issued at December 31, 2002 and 2001, respectively     273     244  
  Additional paid-in capital     320,750     265,809  
  Treasury stock, at cost, 202 and 334 shares at December 31, 2002 and 2001, respectively     (3,733 )   (5,909 )
  Deferred compensation     (1,226 )   (369 )
  Receivables from sales of common stock     (191 )   (1,174 )
  Accumulated other comprehensive income (loss), net of tax     3,290     (15,592 )
  Retained earnings (accumulated deficit)     3,098     (16,482 )
   
 
 
      Total stockholders' equity     322,261     226,527  
   
 
 
      Total liabilities and stockholders' equity   $ 727,285   $ 556,857  
   
 
 

See accompanying notes to consolidated financial statements.

F-3



UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Consolidated Statements of Operations

(in thousands, except per share amounts)

 
  Years ended December 31,
 
 
  2002
  2001
  2000
 
Net patient service revenue   $ 298,694     210,261     133,488  
Management and administrative services revenue     31,238     26,149     2,158  
Equity in earnings of unconsolidated affiliates     9,454     5,879     844  
Other income     3,000     2,079     1,918  
   
 
 
 
    Total revenues     342,386     244,368     138,408  
   
 
 
 
Salaries, benefits and other employee costs     87,872     64,255     44,246  
Medical services and supplies     66,075     48,791     34,883  
Other operating expenses     60,860     45,551     22,922  
General and administrative expenses     23,690     22,364     12,103  
Provision for doubtful accounts     6,330     3,517     2,467  
Depreciation and amortization     26,530     26,116     14,138  
   
 
 
 
    Total operating expenses     271,357     210,594     130,759  
   
 
 
 
    Operating income     71,029     33,774     7,649  
Interest income     792     852     912  
Interest expense     (25,721 )   (18,120 )   (12,540 )
Loss on early retirement of debt (note 8)         (7,466 )    
Impairment of investment securities (note 7)     (1,057 )        
Other     (151 )   146     (782 )
   
 
 
 
    Total other expense, net     (26,137 )   (24,588 )   (12,410 )
   
 
 
 
    Income (loss) before minority interest     44,892     (9,186 )   (4,761 )
Minority interest in income of consolidated subsidiaries     (14,846 )   (7,558 )   (2,332 )
   
 
 
 
    Income (loss) before income taxes     30,046     1,628     (7,093 )
Income tax (expense) benefit (note 13)     (10,446 )   1,122     (1,070 )
   
 
 
 
    Net income (loss)     19,600     2,750     (8,163 )
Preferred stock dividends         (2,684 )   (5,971 )
   
 
 
 
    Net income (loss) attributable to common stockholders   $ 19,600     66     (14,134 )
   
 
 
 
Net income (loss) per share attributable to common stockholders (note 15):                    
  Basic   $ 0.79   $   $ (1.80 )
  Diluted   $ 0.75   $   $ (1.80 )
Weighted average number of common shares:                    
  Basic     24,925     18,380     7,850  
  Diluted     26,056     19,291     7,850  

See accompanying notes to consolidated financial statements.

F-4



UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income (Loss)

(in thousands)

 
  Years Ended December 31,
 
 
  2002
  2001
  2000
 
Net income (loss)   $ 19,600   2,750   (8,163 )
Other comprehensive income (loss), net of taxes:                
  Foreign currency translation adjustments     20,364   (3,566 ) (4,759 )
  Minimum pension liability adjustment     (1,529 )    
  Unrealized gains on securities     47      
   
 
 
 
      Other comprehensive income (loss)     18,882   (3,566 ) (4,759 )
   
 
 
 
      Comprehensive income (loss)   $ 38,482   (816 ) (12,922 )
   
 
 
 

See accompanying notes to consolidated financial statements.

F-5


UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES
Consolidated Statements of Stockholders' Equity
For the years ended December 31, 2002, 2001 and 2000
(in thousands)

 
  Series C Preferred Stock
  Common stock
   
   
   
   
   
   
   
 
 
   
   
   
  Receivables
from sales
of common
stock

  Accumulated
other
comprehensive
income (loss)

  Retained
earnings
(accumulated
deficit)

   
 
 
  Outstanding
shares

  Liquidation
value

  Outstanding
shares

  Par value
  Additional
paid-in
capital

  Treasury
stock

  Deferred
compensation

  Total
 
Balance, December 31, 1999     $   7,306   $ 73   55,984   (344 )   (1,104 ) (7,266 ) (10,772 ) 36,571  
Issuance of common stock and exercise of stock options         983     10   10,429       (1,869 )     8,570  
Issuance of Series C preferred stock   19     15,950         (7 )           15,943  
Issuance of warrants               2,800             2,800  
Issuance of stock options               505     (505 )        
Amortization of deferred compensation                   10       10   10  
Accrued dividends on preferred stock       3,797         (5,971 )           (2,174 )
Net loss                         (8,163 ) (8,163 )
Foreign currency translation adjustments, net of taxes                       (4,760 )   (4,760 )
   
 
 
 
 
 
 
 
 
 
 
 
Balance, December 31, 2000   19     19,747   8,289     83   63,740   (344 ) (495 ) (2,973 ) (12,026 ) (18,935 ) 48,797  
Issuance of common stock and exercise of stock options         13,904     139   180,978   1,086     454     (297 ) 182,360  
Accrued dividends on preferred stock       594         (2,684 )           (2,090 )
Issuance of warrants               169             169  
Repurchases of common stock         (341 )       (6,651 )   1,345       (5,306 )
Conversion of Series C convertible preferred stock   (19 )   (20,341 ) 1,937     19   20,322              
Conversion of convertible subordinated note         313     3   3,284             3,287  
Amortization of deferred compensation                   126         126  
Net income                         2,750   2,750  
Foreign currency translation adjustments, net of taxes                       (3,566 )   (3,566 )
   
 
 
 
 
 
 
 
 
 
 
 
Balance, December 31, 2001         24,102     244   265,809   (5,909 ) (369 ) (1,174 ) (15,592 ) (16,482 ) 226,527  
Issuance of common stock and exercise of stock options         3,034     29   54,667   3,035   (1,230 ) 983     (20 ) 57,464  
Repurchases of common stock         (32 )     274   (859 )         (585 )
Amortization of deferred compensation                   373         373  
Net income                         19,600   19,600  
Foreign currency translation adjustments, net of taxes                       20,364     20,364  
Unrealized gains on securities                       47     47  
Minimum pension liability adjustment                       (1,529 )   (1,529 )
   
 
 
 
 
 
 
 
 
 
 
 
Balance, December 31, 2002     $   27,104   $ 273   320,750   (3,733 ) (1,226 ) (191 ) 3,290   3,098   322,261  
   
 
 
 
 
 
 
 
 
 
 
 

See accompanying notes to consolidated financial statements.

 

 

 

F-6



UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(in thousands)

 
  Years ended December 31,
 
 
  2002
  2001
  2000
 
Cash flows from operating activities:                
  Net income (loss)   $ 19,600   2,750   (8,163 )
  Adjustments to reconcile net income (loss) to net cash provided by operating activities:                
    Provision for doubtful accounts     6,330   3,517   2,467  
    Depreciation and amortization     26,530   26,116   14,138  
    Amortization of discount on debt and debt issue costs     1,374   301   211  
    Deferred income taxes     8,591   (3,648 ) (837 )
    Gain on equipment disposals     34   (188 )  
    Impairment of investment securities     1,057      
    Loss on early retirement of debt       7,466    
    Equity in earnings of unconsolidated affiliates     (9,454 ) (5,879 ) (844 )
    Minority interest in income of consolidated subsidiaries     14,846   7,558   2,332  
    Amortization of deferred compensation     373   126   10  
    Increases (decreases) in cash from changes in operating assets and liabilities, net of effects from purchases of new businesses:                
        Patient receivables     (8,904 ) (6,347 ) (4,611 )
        Other receivables     (1,918 ) 5,918   (571 )
        Inventories of supplies, prepaids and other current assets     (2,843 ) 2,847   1,363  
        Accounts payable and accrued expenses     5,395   2,304   1,710  
        Other long-term liabilities     (1,806 ) (1,984 ) 3,797  
   
 
 
 
          Net cash provided by operating activities     59,205   40,857   11,002  
   
 
 
 
Cash flows from investing activities:                
  Purchases of new businesses, net of cash received     (62,389 ) (57,388 ) (83,283 )
  Purchases of property and equipment     (30,079 ) (25,777 ) (16,893 )
  Sale of property     789   1,042   17,379  
  Increase in deposits     180   (2,102 ) (3,704 )
  Cash released from escrow       1,664   11,436  
   
 
 
 
        Net cash used in investing activities     (91,499 ) (82,561 ) (75,065 )
   
 
 
 
Cash flows from financing activities:                
  Proceeds from long-term debt     59,442   269,288   85,941  
  Payments on long-term debt     (64,388 ) (274,371 ) (42,169 )
  Proceeds from issuance of common stock     53,665   132,818   5,069  
  Payments to repurchase common stock       (104 )  
  Proceeds from issuance of preferred stock and warrants         18,743  
  Payments for the redemption and dividends of preferred stock       (54,908 ) (5,235 )
  Distributions on investments in affiliates     (3,309 ) (552 ) 842  
   
 
 
 
          Net cash provided by financing activities     45,410   72,171   63,191  
   
 
 
 
Effect of exchange rate changes on cash     574   (37 ) 607 )
   
 
 
 
Net increase (decrease) in cash and cash equivalents     13,690   30,430   (265 )
Cash and cash equivalents at beginning of year     33,881   3,451   3,716  
   
 
 
 
Cash and cash equivalents at end of year   $ 47,571   33,881   3,451  
   
 
 
 
Supplemental information:                
  Interest paid, net of amounts capitalized   $ 24,779   20,424   8,204  
  Income taxes paid     3,090      
  Non-cash transactions:                
    Debt issued for purchases of new business         54,012  
    Repurchases of common stock using noncash assets       70   1,076  
    Issuance of common stock for service contracts     1,002      
    Sale of common stock for notes receivable from employees, net       70   1,076  
    Common stock, options, and warrants issued for purchases of new businesses     1,186   48,949   3,500  
    Conversion of convertible preferred stock to common       20,341   70  
    Accrued dividends on preferred stock         5,971  
    Assets acquired under capital lease obligations     2,382   7,053   18,913  
    Conversion of subordinated debt to redeemable preferred stock       20,000    
    Conversion of subordinated debt to common stock       3,287    

See accompanying notes to consolidated financial statements.

F-7



UNITED SURGICAL PARTNERS INTERNATIONAL, INC.
AND SUBSIDIARIES

Notes to Consolidated Financial Statements

December 31, 2002 and 2001

(1)
Summary of Significant Accounting Policies and Practices

(a)
Description of Business

F-8


F-9



F-10


 
  Years Ended December 31,
 
 
  2002
  2001
  2000
 
Net income (loss) attributable to common stockholders                    
  As reported   $ 19,600   $ 66   $ (14,134 )
  Pro forma     16,187     (792 )   (14,615 )
Basic earnings (loss) per share                    
  As reported   $ 0.79         (1.80 )
  Pro forma     0.65     (0.04 )   (1.86 )
Diluted earnings (loss) per share                    
  As reported   $ 0.75         (1.80 )
  Pro forma     0.62     (0.04 )   (1.86 )

F-11


(2)
Offerings of Common Stock and Senior Subordinated Notes

F-12


(3)
Acquisitions and Equity Investments
Goodwill   $ 45,333
Management contracts not subject to amortization (indefinite)     2,816
Management contracts subject to amortization     1,469
   
Total   $ 49,618

F-13


 
  Years ended December 31
(unaudited)

 
  2002
  2001
Net revenues   $ 362,706   $ 285,409
Net income     20,186     5,214
Diluted earnings per share     0.77     0.13
(4)
Other Receivables
(5)
Property and Equipment
 
  Estimated
useful lives

  2002
  2001
 
Land and land improvements     $ 24,690   $ 21,882  
Buildings and leasehold improvements   7-50 years     164,068     129,042  
Equipment   3-12 years     168,534     115,664  
Furniture and fixtures   4-20 years     13,216     11,793  
Construction in progress         22,087     12,717  
       
 
 
          392,595     291,098  
Less accumulated depreciation         (122,208 )   (79,497 )
       
 
 
  Net property and equipment       $ 270,387   $ 211,601  
       
 
 

F-14


 
  2002
  2001
 
Land and buildings   $ 54,267   $ 22,722  
Equipment and furniture     39,443     33,791  
   
 
 
      93,710     56,513  
Less accumulated amortization     (24,080 )   (16,271 )
   
 
 
  Net property and equipment under capital leases   $ 69,630   $ 40,242  
   
 
 
(6)
Goodwill and Intangible Assets

F-15


 
  Year ended December 31,
 
 
  2002
  2001
  2000
 
Net income (loss) attributable to common shareholders, as reported   $ 19,600   $ 66   $ (14,134 )
Amortization of goodwill and indefinite-lived intangible assets, net of applicable income tax benefits         4,184     4,170  
   
 
 
 
Net income (loss) attributable to common shareholders, as reported   $ 19,600   $ 4,250   $ (9,964 )
   
 
 
 

Diluted earnings per share, as reported

 

$

0.75

 

$


 

$

(1.80

)
Amortization of goodwill and indefinite-lived intangible assets, net of applicable income tax benefits         0.22     0.53  
   
 
 
 
Pro forma diluted earnings per share   $ 0.75   $ 0.22   $ (1.27 )
   
 
 
 
 
  December 31,
 
  2002
  2001
Goodwill   $ 215,498   $ 151,804
Other intangible assets     72,086     64,005
   
 
  Total   $ 287,584   $ 215,809
   
 
 
   
  Western Europe
   
 
  U.S.
  Spain
  United
Kingdom

  Western
Europe
Total

  Total
Balance at December 31, 2001   $ 106,579   $ 26,914   $ 18,311   $ 45,225   $ 151,804
Additions     46,356     10,632         10,632     56,988
Other         4,752     1,954     6,706     6,706
   
 
 
 
 
Balance at December 31, 2002   $ 152,935   $ 42,298   $ 20,265   $ 62,563   $ 215,498
   
 
 
 
 

F-16


 
  December 31, 2001
 
  Gross
Carrying
Amount

  Accumulated
Amortization

  Total
Definite Useful Lives                  
Management Contracts   $ 23,174   $ (3,747 ) $ 19,427
Other     7,831     (717 )   7,114
   
 
 
  Total   $ 31,005   $ (4,464 ) $ 26,541
   
 
     
Indefinite Useful Lives                  
Management Contracts               $ 37,362
Other                 102
               
  Total               $ 37,464
               
  Total intangible assets               $ 64,005
               
 
  December 31, 2002
 
  Gross
Carrying
Amount

  Accumulated
Amortization

  Total
Definite Useful Lives                  
Management Contracts   $ 26,190   $ (6,259 ) $ 19,931
Other     11,966     (2,264 )   9,702
   
 
 
  Total   $ 38,156   $ (8,523 ) $ 29,633
   
 
     
Indefinite Useful Lives                  
Management Contracts               $ 42,334
Other                 119
               
  Total               $ 42,453
               
  Total intangible assets               $ 72,086
               

F-17


2003   $ 2,416
2004     1,892
2005     1,754
2006     1,750
2007     1,578
   
    $ 9,390
   
(7)
Long-Term Investments

F-18


(8)
Long-term Debt
 
  2002
  2001
 
Senior credit agreements   $ 53,724   $ 35,443  
Senior subordinated notes     148,910     148,837  
Notes payable to financial institution     7,332     5,000  
Loans from former owners of subsidiaries     1,719     11,121  
Capital lease obligations     65,018     38,280  
   
 
 
  Total long-term debt     276,703     238,681  
Less current portion     (13,132 )   (10,640 )
   
 
 
  Long-term debt, less current portion   $ $263,571   $ 228,041  
   
 
 

F-19


Period

  Redemption Price
 
2006   105.000 %
2007   103.333 %
2008   101.667 %
2009   100.000 %
2010   100.000 %

F-20


(9)
Leases
 
  Capital
leases

  Operating
leases

Year ending December 31,            
2003   $ 13,091   $ 7,690
2004     11,386     7,124
2005     9,529     6,630
2006     6,449     6,387
2007     5,538     5,990
Thereafter     90,106     26,214
   
 
  Total minimum lease payments   $ 136,099   $ 60,035
         
Amount representing interest     (71,081 )    
   
     
  Present value of minimum lease payments   $ 65,018      
   
     

F-21


(10)
Preferred Stock
Series A Redeemable Preferred Stock, $0.01 par value   31,200
Series B Convertible Redeemable Preferred Stock, $0.01 par value   2,716
Series C Convertible Preferred Stock, $0.01 par value   20,000
Series D Redeemable Preferred Stock, $0.01 par value   40,000
Series A Junior Participating Preferred Stock, $0.01 par value   500,000
Not designated   9,460,000
   
  Total authorized shares of Preferred Stock   10,053,916
   
(11)
Stockholders' Equity

F-22


(12)
Related Party Transactions

F-23


(13)
Income Taxes
 
  2002
  2001
  2000
 
Domestic   $ 24,423   $ 2,219   $ (4,960 )
Foreign     5,623     (591 )   (2,133 )
   
 
 
 
    $ 30,046   $ 1,628   $ (7,093 )
   
 
 
 
 
  Current
  Deferred
  Total
Year ended December 31, 2002:                  
  U.S. federal   $   $ 8,503   $ 8,503
  State and local     809     460     1,269
  Foreign     1,046     (372 )   674
   
 
 
    Net income tax expense   $ 1,855   $ 8,591   $ 10,446
   
 
 

F-24


 
  Current
  Deferred
  Total
 
Year ended December 31, 2001:                    
  U.S. federal   $ 20   $ (2,923 ) $ (2,903 )
  State and local     767         767  
  Foreign     1,739     (725 )   1,014  
   
 
 
 
    Net tax expense (benefit)   $ 2,526   $ (3,648 ) $ (1,122 )
   
 
 
 
 
  Current
  Deferred
  Total
Year ended December 31, 2000:                  
  U.S. federal   $   $   $
  State and local     248         248
  Foreign     1,659     (837 )   822
   
 
 
    Net tax expense (benefit)   $ 1,907   $ (837 ) $ 1,070
   
 
 
 
  Years Ended December 31,
 
 
  2002
  2001
  2000
 
Computed "expected" tax expense (benefit)   $ 10,516   $ 554   $ (2,412 )
Increase (reduction) in income taxes resulting from:                    
  Net operating loss carryforwards     348     904     2,661  
  Differences between U.S. financial reporting and foreign statutory reporting     3,362     452     (949 )
  State tax expense (benefit)     998     767     (250 )
  Removal of foreign tax rate differential     (216 )   (160 )    
  Goodwill     296     1,193     240  
  Change in valuation allowance     (4,888 )   (4,398 )   2,078  
  Equity investment in foreign subsidiary             (195 )
  Other     30     (434 )   (103 )
   
 
 
 
    Total   $ 10,446   $ (1,122 ) $ 1,070  
   
 
 
 

F-25


 
  Years Ended December 31,
 
 
  2002
  2001
 
Deferred tax assets:              
  Net operating loss carryforwards   $ 14,744   $ 16,604  
  Basis difference of property and equipment     1,908     1,556  
  Basis difference in start-up costs     701     421  
  Spanish tax credit     66     594  
  Foreign withholding tax credit     505     491  
  Alternative minimum tax credit     832     866  
  Accrued expenses     3,412     3,928  
  Bad debts     2,125     786  
   
 
 
    Total deferred tax assets     27,157     27,289  
Less valuation allowance     (5,652 )   (10,540 )
   
 
 
    Net deferred tax assets   $ 18,641   $ 14,706  
   
 
 
Deferred tax liabilities:              
  Capitalized interest   $ 760   $ 225  
  Basis difference of acquisitions     24,636     17,781  
  Capital leases     35     35  
  Accelerated depreciation     6,149     3,550  
  Accrued pension obligation     25     250  
  Prepaid expenses     956      
  Other         3  
   
 
 
    Total deferred tax liabilities   $ 32,561   $ 21,844  
   
 
 

F-26


(14)
Equity-Based Compensation

F-27


 
  Years Ended December 31,
 
 
  2002
  2001
  2000
 
Expected life in years   5.0   5.0   5.0  
Interest rate   4.0 % 4.6 % 5.0 %
Dividend yield   0.0 % 0.0 % 0.0 %
Volatility   40.0 % 40.0 % 40.0 %
 
  Number of
shares

  Weighted
average
exercise
price

Balance at December 31, 1999   856,933   $ 9.00
  Granted   506,000     12.90
  Exercised   (5,000 )   6.00
  Forfeited   (28,167 )   10.68
  Expired      
   
 
Balance at December 31, 2000   1,329,766     10.47
  Granted   1,676,474     15.73
  Exercised   (114,205 )   5.57
  Forfeited   (33,071 )   14.04
  Expired      
   
 
Balance at December 31, 2001   2,858,964   $ 13.62
  Granted   888,233     24.84
  Exercised   (372,121 )   7.13
  Forfeited   (131,486 )   18.34
  Expired      
   
 
Balance at December 31, 2002   3,243,590   $ 17.24
   
 
Shares exercisable at December 31, 2000   422,368   $ 8.55
Shares exercisable at December 31, 2001   942,369   $ 9.33
Shares exercisable at December 31, 2002   1,199,493   $ 12.36

F-28


Range of exercise prices

  Stock
options
outstanding

  Weighted
average
exercise
price

  Weighted
average
remaining
contractual
life

$2.55-$13.50   1,318,393   $ 10.84   6.77
$14.00-$22.84   1,110,468   $ 18.55   8.27
$25.44-$27.60   814,729   $ 25.83   9.20
   
 
 
    3,243,590   $ 17.24   7.89
   
 
 
Range of exercise prices

  Stock options
Exercisable

  Weighted average
exercise price

$2.55-$13.50   901,184   $ 9.84
$14.00-$22.84   235,664   $ 18.54
$25.44-$27.60   62,645   $ 25.44
   
 
    1,199,493   $ 12.36
   
 


Employee Stock Purchase Plan

        USPI adopted an Employee Stock Purchase Plan on February 13, 2001. The plan provides for the grant of stock options to selected eligible employees. Any eligible employee may elect to participate in the plan by authorizing USPI's options and compensation committee to make payroll deductions to pay the exercise price of an option at the time and in the manner prescribed by USPI's options and compensation committee. This payroll deduction may be a specific amount or a designated percentage to be determined by the employee, but the specific amount may not be less than an amount established by the Company and the designated percentage may not exceed an amount of eligible compensation established by the Company from which the deduction is made. The Company has reserved 500,000 shares of common stock for this plan of which 69,183 and 61,377 were issued during 2002 and 2001, respectively.

(15)
Earnings Per Share

F-29


 
  Years ended December 31,
 
 
  2002
  2001
  2000
 
Net income (loss) attributable to common stockholders   $ 19,600   $ 66   $ (14,134 )
Weighted average common shares outstanding     24,925     18,380     7,850  
Effect of dilutive securities:                    
  Stock options     841     634     (A )
  Warrants and restricted stock     290     277     (A )
  Convertible subordinated debt     (B )   (A )   (A )
  Series C convertible preferred stock     (B )   (A )   (A )
   
 
 
 
Shares used for diluted earnings (loss) per share     26,056     19,291     7,850  
   
 
 
 
Basic earnings (loss) per share   $ 0.79   $   $ (1.80 )
Diluted earnings (loss) per share   $ 0.75   $   $ (1.80 )
(A)
No incremental shares are included because the effect would be antidilutive.

(B)
No securities of this type were outstanding during this period.
(16)
Segment Disclosures

F-30


 
   
  Western Europe
   
 
2002 (in thousands)

  U.S.
  Spain
  United
Kingdom

  Western
Europe
Total

  Total
 
Net patient service revenue   $ 164,770   $ 86,490   $ 47,434   $ 133,924   $ 298,694  
Other revenue     41,065     2,627         2,627     43,692  
   
 
 
 
 
 
  Total revenues   $ 205,835   $ 89,117   $ 47,434   $ 136,551   $ 342,386  
   
 
 
 
 
 
Depreciation and amortization   $ 15,427   $ 7,407   $ 3,696   $ 11,103   $ 26,530  
Operating income     55,221     7,078     8,730     15,808     71,029  
Net interest income (expense)     (20,060 )   (2,397 )   (2,472 )   (4,869 )   (24,929 )
Income tax benefit (expense)     (9,961 )   878     (1,363 )   (485 )   (10,446 )
Total assets     437,351     168,604     121,330     289,934     727,285  
Capital expenditures     11,663     7,468     13,330     20,798     32,461  
 
   
  Western Europe
   
 
2001 (in thousands)

  U.S.
  Spain
  United
Kingdom

  Western
Europe
Total

  Total
 
Net patient service revenue   $ 101,694   $ 69,583   $ 38,984   $ 108,567   $ 210,261  
Other revenue     32,245     1,862         1,862     34,107  
   
 
 
 
 
 
  Total revenues   $ 133,939   $ 71,445   $ 38,984   $ 110,429   $ 244,368  
   
 
 
 
 
 
Depreciation and amortization   $ 14,598   $ 7,976   $ 3,542   $ 11,518   $ 26,116  
Operating income     25,634     2,021     6,119     8,140     33,774  
Net interest income (expense)     (10,993 )   (3,244 )   (3,031 )   (6,275 )   (17,268 )
Income tax benefit (expense)     1,962     186     (1,026 )   (840 )   1,122  
Total assets     356,226     116,500     84,131     200,631     556,857  
Capital expenditures     20,598     5,283     6,949     12,232     32,830  
 
   
  Western Europe
   
 
2000 (in thousands)

  U.S.
  Spain
  United
Kingdom

  Western
Europe
Total

  Total
 
Net patient service revenue   $ 50,143   $ 57,116   $ 26,229   $ 83,345   $ 133,488  
Other revenue     3,366     1,554         1,554     4,920  
   
 
 
 
 
 
  Total revenues   $ 53,509   $ 58,670   $ 26,229   $ 84,899   $ 138,408  
   
 
 
 
 
 
Depreciation and amortization   $ 5,317   $ 6,335   $ 2,486   $ 8,821   $ 14,138  
Operating income     3,835     446     3,368     3,814     7,649  
Net interest income (expense)     (7,335 )   (1,421 )   (2,872 )   (4,293 )   (11,628 )
Income tax benefit (expense)     (248 )   (688 )   (134 )   (822 )   (1,070 )
Total assets     111,549     121,728     97,119     218,847     330,396  
Capital expenditures     5,614     27,720     2,472     30,192     35,806  

F-31


(17)
Commitments and Contingencies

(a)
Financial Guarantees

F-32


(18)
Subsequent Events
(19)
Condensed Consolidating Financial Statements

F-33



Condensed Consolidating Balance Sheets:

As of December 31, 2002

  USPI and
Wholly-owned
U.S. Subsidiaries

  Non-participating
Investees

  Consolidation
Adjustments

  Consolidated
Total

Assets:                        
Current assets:                        
Cash and cash equivalents   $ 24,712   $ 22,859   $   $ 47,571
Accounts receivable, net     90     39,086         39,176
Other receivables     46,983     9,281     (21,529 )   34,735
Inventories     280     7,476         7,756
Other     10,235     2,423         12,658
   
 
 
 
  Total current assets     82,300     81,125     (21,529 )   141,896
Property and equipment, net     39,236     231,743     (592 )   270,387
Investments in affiliates     172,050     375     (153,729 )   18,696
Intangible assets, net     166,036     122,685     (1,137 )   287,584
Other     98,647     5,204     (95,129 )   8,722
   
 
 
 
  Total assets   $ 558,269   $ 441,132   $ (272,116 ) $ 727,285
   
 
 
 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

 

 

 

 
Current liabilities:                        
Accounts payable   $ 1,357   $ 24,619   $ 13   $ 25,989
Accrued expenses     28,543     22,769     51     51,363
Current portion of long-term debt     2,453     11,937     (1,258 )   13,132
   
 
 
 
  Total current liabilities     32,353     59,325     (1,194 )   90,484
Long-term debt     158,199     216,621     (111,249 )   263,571
Other liabilities     7,936     16,173         24,109
Minority interests         7,387     19,473     26,860
Redeemable preferred stock                
Stockholders' equity     359,781     141,626     (179,146 )   322,261
   
 
 
 
  Total liabilities and stockholders' equity   $ 558,269   $ 441,132   $ (272,116 ) $ 727,285
   
 
 
 

F-34


As of December 31, 2001

  USPI and
Wholly-owned
U.S. Subsidiaries

  Non-participating
Investees

  Consolidation
Adjustments

  Consolidated
Total

Assets:                        
Current assets:                        
Cash and cash equivalents   $ 20,396   $ 13,485   $   $ 33,881
Accounts receivable, net     418     27,538     (410 )   27,546
Other receivables     47,087     (11,174 )   (5,334 )   30,579
Inventories     223     5,462         5,685
Other     9,298     3,464         12,762
   
 
 
 
  Total current assets     77,422     38,775     (5,744 )   110,453
Property and equipment, net     41,767     170,449     (615 )   211,601
Investments in affiliates     165,437     170     (153,279 )   12,328
Intangible assets, net     119,596     97,350     (1,137 )   215,809
Other     88,148     33,777     (115,259 )   6,666
   
 
 
 
  Total assets   $ 492,370   $ 340,521   $ (276,034 ) $ 556,857
   
 
 
 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

 

 

 

 
Current liabilities:                        
Accounts payable   $ 2,121   $ 18,512   $   $ 20,633
Accrued expenses     24,758     13,733     404     38,895
Current portion of long-term debt     2,433     8,841     (634 )   10,640
   
 
 
 
  Total current liabilities     29,312     41,086     (230 )   70,168
Long-term debt     158,170     186,093     (116,222 )   228,041
Other liabilities     1,936     14,110         16,046
Minority interests         5,958     10,117     16,075
Redeemable preferred stock                
Stockholders' equity     302,952     93,274     (169,699 )   226,527
   
 
 
 
  Total liabilities and stockholders' equity   $ 492,370   $ 340,521   $ (276,034 ) $ 556,857
   
 
 
 

F-35



Condensed Consolidating Statements of Operations:

Year ended December 31, 2002

  USPI and
Wholly-owned
U.S. Subsidiaries

  Non-participating
Investees

  Consolidation
Adjustments

  Consolidated
Total

 
Revenues   $ 69,932   $ 283,558   $ (11,104 ) $ 342,386  
Operating expenses, excluding depreciation and amortization     45,352     210,847     (11,372 )   244,827  
Depreciation and amortization     9,726     16,828     (24 )   26,530  
   
 
 
 
 
Operating income (loss)     14,854     55,883     292     71,029  
Interest income (expense), net     (12,039 )   (12,890 )       (24,929 )
Other expense     292     (1,208 )   (292 )   (1,208 )
   
 
 
 
 
Income (loss) before minority interests     3,107     41,785         44,892  
Minority interests in income of consolidated subsidiaries         (7,148 )   (7,698 )   (14,846 )
   
 
 
 
 
Income (loss) before income taxes     3,107     34,637     (7,698 )   30,046  
Income tax (expense) benefit     (9,441 )   (1,005 )       (10,446 )
   
 
 
 
 
Net income (loss)   $ (6,334 ) $ 33,632   $ (7,698 ) $ 19,600  
   
 
 
 
 
Year ended December 31, 2001

  USPI and
Wholly-owned
U.S. Subsidiaries

  Non-participating
Investees

  Consolidation
Adjustments

  Consolidated
Total

 
Revenues   $ 55,537   $ 194,611   $ (5,780 ) $ 244,368  
Operating expenses, excluding depreciation and amortization     39,478     150,814     (5,814 )   184,478  
Depreciation and amortization     9,782     16,592     (258 )   26,116  
   
 
 
 
 
Operating income (loss)     6,277     27,205     292     33,774  
Interest income (expense), net     (6,353 )   (10,928 )   13     (17,268 )
Other expense     (4,899 )   (2,181 )   (240 )   (7,320 )
   
 
 
 
 
Income (loss) before minority interests     (4,975 )   14,096     65     9,186  
Minority interests in income of consolidated subsidiaries         (4,058 )   (3,500 )   (7,558 )
   
 
 
 
 
Income (loss) before income taxes     (4,975 )   10,038     (3,435 )   1,628  
Income tax (expense) benefit     2,056     (934 )       (1,122 )
   
 
 
 
 
Net income (loss)   $ (2,919 ) $ 9,104   $ (3,435 ) $ 2,750  
   
 
 
 
 

F-36


Year ended December 31, 2000

  USPI and
Wholly-owned
U.S. Subsidiaries

  Non-participating
Investees

  Consolidation
Adjustments

  Consolidated
Total

 
Revenues   $ 5,590   $ 136,394   $ (3,576 ) $ 138,408  
Operating expenses, excluding depreciation and amortization     11,406     109,059     (3,844 )   116,621  
Depreciation and amortization     2,043     12,135     (40 )   14,138  
   
 
 
 
 
Operating income (loss)     (7,859 )   15,200     308     7,649  
Interest income (expense), net     (3,127 )   (8,517 )   16     (11,628 )
Other income (expense)     499     (3,251 )   1,970     (782 )
   
 
 
 
 
Income (loss) before minority interests     (10,487 )   3,432     2,294     (4,761 )
Minority interests in income of consolidated subsidiaries         (1,358 )   (974 )   (2,332 )
   
 
 
 
 
Income (loss) before income taxes     (10,487 )   2,074     1,320     (7,093 )
Income tax (expense) benefit     (223 )   (847 )       (1,070 )
   
 
 
 
 
Net income (loss)   $ (10,710 ) $ 1,227   $ 1,320   $ (8,163 )
   
 
 
 
 


Condensed Consolidating Statements of Cash Flows:

Year ended December 31, 2002

  USPI and
Wholly-owned
U.S. Subsidiaries

  Non-participating
Investees

  Consolidation
Adjustments

  Consolidated
Total

 
Cash flows from operating activities:                          
Net loss   $ (6,333 ) $ 33,632   $ (7,699 ) $ 19,600  
Changes in operating and intercompany assets and liabilities and noncash items included in net loss     23,378     (96,840 )   113,067     39,605  
   
 
 
 
 
Net cash provided by (used in) operating activities     17,045     (63,208 )   105,368     59,205  
Cash flows from investing activities:                          
Purchases of property and equipment, net     (4,661 )   (25,418 )       (30,079 )
Purchases of new businesses     (54,809 )   (7,580 )       (62,389 )
Other items     (517 )   1,486         969  
   
 
 
 
 
  Net cash used in investing activities     (59,987 )   (31,512 )       (91,499 )
Cash flows from financing activities:                          
Long-term borrowings, net     (3,097 )   (1,849 )       (4,946 )
Proceeds from issuance of common stock     53,665     32,716     (32,716 )   53,665  
Other items     (3,309 )   72,110     (72,110 )   (3,309 )
   
 
 
 
 
  Net cash provided by (used in) financing activities     47,259     102,977     (104,826 )   45,410  
Effect of exchange rate changes on cash         1,116     (542 )   574  
Net increase in cash     4,317     9,373         13,690  
Cash at the beginning of the year     20,396     13,485         33,881  
   
 
 
 
 
Cash at the end of the year   $ 24,713   $ 22,858   $   $ 47,571  
   
 
 
 
 

F-37


Year ended December 31, 2001

  USPI and
Wholly-owned
U.S. Subsidiaries

  Non-participating
Investees

  Consolidation
Adjustments

  Consolidated
Total

 
Cash flows from operating activities:                          
Net loss   $ (2,919 ) $ 9,121   $ (3,452 ) $ 2,750  
Changes in operating and intercompany assets and liabilities and noncash items included in net loss     2,636     31,906     3,565     38,107  
   
 
 
 
 
Net cash provided by (used in) operating activities     (283 )   41,027     113     40,857  
Cash flows from investing activities:                          
Purchases of property and equipment, net     (7,130 )   (18,647 )       (25,777 )
Purchases of new businesses     (57,099 )   (415 )   126     (57,388 )
Other items     (27,953 )   (852 )   29,409     604  
   
 
 
 
 
  Net cash provided by (used in) investing activities     (92,182 )   (19,914 )   29,535     (82,561 )
Cash flows from financing activities:                          
Long-term borrowings, net     34,842     (10,516 )   (29,409 )   (5,083 )
Proceeds from issuance of common stock     132,818     239     (239 )   132,818  
Other items     (55,564 )           (55,564 )
   
 
 
 
 
  Net cash provided by (used in) financing activities     112,096     (10,277 )   (29,648 )   72,171  
Effect of exchange rate changes on cash         (37 )       (37 )
Net increase (decrease) in cash     19,631     10,799         30,430  
Cash at inception     765     2,686         3,451  
   
 
 
 
 
Cash at the end of the year   $ 20,396   $ 13,485   $   $ 33,881  
   
 
 
 
 

F-38


Year ended December 31, 2000

  USPI and
Wholly-owned
U.S. Subsidiaries

  Non-participating
Investees

  Consolidation
Adjustments

  Consolidated
Total

 
Cash flows from operating activities:                          
Net income (loss)   $ (10,710 ) $ 1,226   $ 1,321   $ (8,163 )
Changes in operating and intercompany assets and liabilities and noncash items included in net income (loss)     (634 )   21,104     (1,304 )   19,166  
   
 
 
 
 
Net cash provided by (used in) operating activities     (11,344 )   22,330     17     11,003  
Cash flows from investing activities:                          
Sales (purchases) of property and equipment, net     (4,233 )   4,719         486  
Purchases of new businesses     (42,942 )   (65,581 )   25,239     (83,284 )
Other items     4,100     (3,703 )   7,336     7,733  
   
 
 
 
 
  Net cash provided by (used in) investing activities     (43,075 )   (64,565 )   32,575     (75,065 )
Cash flows from financing activities:                          
Long-term borrowings, net     33,750     17,358     (7,336 )   43,772  
Proceeds from issuance of common stock     5,069     25,239     (25,239 )   5,069  
Other items     15,895     (1,545 )       14,350  
   
 
 
 
 
  Net cash provided by (used in) financing activities     54,714     41,052     (32,575 )   63,191  
Effect of exchange rate changes on cash         623     (17 )   606  
Net increase (decrease) in cash     295     (560 )       (265 )
Cash at the beginning of the year     470     3,246         3,716  
   
 
 
 
 
Cash at the end of the year   $ 765   $ 2,686   $   $ 3,451  
   
 
 
 
 
(20)
New Accounting Pronouncements

        In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities. This standard requires that a liability for costs associated with an exit or disposal activity be recognized when the liability is incurred. Under previous accounting standards, a liability for an exit cost (as defined by the standard) was recognized at the date of an entity's commitment to an exit plan. The provisions of SFAS No. 146 are effective for exit or disposal activities initiated after December 31, 2002. To the extent that the Company initiates exit or disposal activities after this date, SFAS No. 146 might have a material effect on its results of operations or financial position.

        In November 2002, the FASB issued Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness to Others (FIN 45). FIN 45 addresses financial accounting for and disclosure of guarantees, requiring certain guarantees issued or modified after December 31, 2002 to be recorded at fair value. This treatment differs from the existing treatment, under SFAS No. 5, Accounting for Contingencies, of recording a liability only when a loss is probable and reasonably estimable. The Company adopted the disclosure requirements, which apply to existing guarantees as well as newly issued ones, as of December 31, 2002. The portion of the standard

F-39



requiring certain guarantees to be recorded at fair value was adopted January 1, 2003, and is not expected to have a material impact on the Company's financial position and results of operations.

        In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based Compensation—Transition and Disclosure. This new standard amends SFAS No. 123, Accounting for Stock-Based Compensation, to provide for alternative methods of transition for an entity that voluntarily changes to the fair value based method of accounting for stock-based employee compensation. In addition, the standard amends the disclosure requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial statements. Certain of the disclosure modifications are required for fiscal years ending after December 15, 2002 and were adopted by the Company as of December 31, 2002.

        In January 2003, the FASB issued Interpretation No. 46, Consolidation of Variable Interest Entities, an Interpretation of ARB No. 51 (FIN 46). FIN 46 addresses the consolidation by business enterprises of variable interest entities, as defined in the Interpretation, and is applicable for years ending after June 15, 2003 to interests in variable interest entities created or obtained after January 31, 2003. The Company does not expect the application of this standard to have a material impact on its financial position or results of operations.

(21)
Selected Quarterly Financial Data (Unaudited)

 
  2001 Quarters
  2002 Quarters
 
  First
  Second
  Third
  Fourth
  First
  Second
  Third
  Fourth
 
  (in thousands, except per share amounts)

  (in thousands, except per share amounts)

Net revenues   $ 53,836   $ 59,896   $ 60,783   $ 69,853   $ 75,078   $ 85,841   $ 85,831   $ 95,636
Net income (loss)     519     1,753     1,724     (1,246 )   4,703     6,114     3,040     5,743
Basic earnings (loss) per share   $ (0.04 ) $ 0.06   $ 0.05   $ (0.07 ) $ 0.20   $ 0.25   $ 0.12   $ 0.21
Diluted earnings (loss) per share   $ (0.04 ) $ 0.06   $ 0.05   $ (0.07 ) $ 0.19   $ 0.24   $ 0.12   $ 0.21

F-40



2.    Financial Statement Schedules

        The following financial statement schedule is filed as part of this Form10-K:

Schedule II—Valuation and Qualifying Accounts   S-1


SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED DECEMBER 31, 2000, 2001 AND 2002

(in thousands)

Allowance for Doubtful Accounts

 
   
  Additions Charged to:
   
   
   
 
  Balance at
Beginning of
Period

  Costs and
Expenses

  Other Accounts
  Deductions(1)
  Other Items(2)
  Balance at
End of Period

2000   $ 2,742   2,467     (2,072 ) 529   3,666
2001     3,666   3,517     (3,445 ) 988   4,726
2002     4,726   6,330     (7,404 ) 3,502   7,154

(1)
Accounts written off.

(2)
Beginning balances for purchased businesses.

        All other schedules are omitted because they are not applicable or not required or because the required information is included in the financial statements or notes thereto.

S-1




(3)    Exhibits:

Exhibit
Number

   
  Description
  2.1   #   Agreement and Plan of Merger, dated as of December 6, 2000, among the Company, OPC Acquisition Corporation and OrthoLink Physicians Corporation (previously filed as Exhibit 2.1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  2.2   #   Agreement for the Sale and Purchase of Shares and Loan Notes in Aspen Healthcare Holdings Limited, dated April 6, 2000, between Electra Private Equity Partners 1995 and others and Global Healthcare Partners Limited (previously filed as Exhibit 2.2 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  2.3   #   Agreement and Plan of Reorganization, dated as of March 26, 2002, by and among the Company, USP Acquisition Corporation, Surgicoe Corporation and each of the shareholders of Surgicoe named in the agreement (previously filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Commission on April 16, 2002 and incorporated herein by reference)
  3.1   #   Second Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to Amendment No. 4 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  3.2   #   Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the Company's Registration Statement on Form S-3 (No. 333-99309) and incorporated herein by reference)
  4.1   #   Form of Common Stock Certificate (previously filed as Exhibit 4.1 to Amendment No. 4 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.2   #   Indenture, dated as of December 19, 2001, among United Surgical Partners Holdings, Inc., the guarantor parties thereto and U.S. Trust Company of Texas, N.A. (previously filed as Exhibit 4.2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and incorporated herein by reference)
  4.3   #   Global Security, dated as of December 19, 2001, governing United Surgical Partners Holdings, Inc.'s outstanding 10% Senior Subordinated Notes due 2011 (previously filed as Exhibit 4.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and incorporated herein by reference)
  4.4   #   Third Amended and Restated Stockholders' Agreement, dated March 27, 2000, by and among the Company and the security holders named therein (previously filed as Exhibit 4.2 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.1   #   Amended and Restated Registration Rights Agreement, dated April 30, 1998, by and among the Company and the security holders named therein (the "Registration Rights Agreement") (previously filed as Exhibit 4.3.1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.2   #   Amendment No. 1 to the Registration Rights Agreement, dated as of June 26, 1998, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.2 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.3   #   Amendment No. 2 to the Registration Rights Agreement, dated as of July 31, 1998, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.3 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)

II-1


  4.5.4   #   Amendment No. 3 to the Registration Rights Agreement, dated as of October 26, 1998, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.4 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.5   #   Amendment No. 4 to the Registration Rights Agreement, dated as of December 22, 1998, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.5 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.6   #   Amendment No. 5 to the Registration Rights Agreement, dated as of June 1, 1999, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.6 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.7   #   Amendment No. 6 to the Registration Rights Agreement, dated as of March 27, 2000, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.7 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.8   #   Amendment No. 7 to the Registration Rights Agreement, dated as of February 12, 2001, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.8 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.6   #   Rights Agreement between the Company and First Union National Bank as Rights Agent dated June 13, 2001 (previously filed as Exhibit 4.1 to the Company's Form 8-A filed with the Commission on June 13, 2001 and incorporated herein by reference)
10.1   #   Credit Agreement, dated April 6, 2000, by and among Global Healthcare Partners Limited and the Governor and Company of the Bank of Scotland (previously filed as Exhibit 10.3 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.2   #   Second Amended and Restated Credit Agreement, dated as of November 7, 2002, among USP Domestic Holdings, Inc., USPE Holdings Limited, various financial institutions from time to time parties thereto as the lenders and Sun Trust Bank, as Administrative Agent (previously filed as Exhibit 10.1 to the Company's Annual Report on Form 10-Q for the quarter ended September 30, 2002 and incorporated herein by reference)
10.3   #   Contribution and Purchase Agreement, dated as of May 11, 1999, by and among USP North Texas, Inc., Baylor Health Services, Texas Health Ventures Group LLC and THVG/Health First L.L.C. (previously filed as Exhibit 10.11 to Amendment No. 2 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.4   #   Common Stock Purchase Warrant, dated June 1, 1999 (previously filed as Exhibit 10.15 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.5   #   Stock Purchase Warrant, dated March 27, 2000 (previously filed as Exhibit 10.16 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.6   *   Employment Agreement, dated as of November 15, 2002, by and between the Company and Donald E. Steen
10.7   *   Employment Agreement, dated as of November 15, 2002, by and between the Company and William H. Wilcox

II-2


10.8   #   Stock Option and Restricted Stock Purchase Plan (previously filed as Exhibit 10.19 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.9   #   2001 Equity-Based Compensation Plan (previously filed as Exhibit 10.20 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.10   #   Employee Stock Purchase Plan (previously filed as Exhibit 10.21 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.11   #   Deferred Compensation Plan, effective as of February 12, 2002 (previously filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2002 and incorporated herein by reference)
10.12   #   Supplemental Retirement Plan, effective as of February 12, 2002 (previously filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2002 and incorporated herein by reference)
10.13   #   Form of Indemnification Agreement between the Company and its directors and officers (previously filed as Exhibit 10.22 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
21.1   *   List of the Company's subsidiaries.
23.1   *   Consent of KPMG LLP for United Surgical Partners International, Inc.
24.1   *   Power of Attorney—Donald E. Steen
24.2   *   Power of Attorney—William H. Wilcox
24.3   *   Power of Attorney—Mark A. Kopser
24.4   *   Power of Attorney—John J. Wellik
24.5   *   Power of Attorney—James C. Crews
24.6   *   Power of Attorney—D. Scott Mackesy
24.7   *   Power of Attorney—Thomas L. Mills
24.8   *   Power of Attorney—Boone Powell, Jr.
24.9   *   Power of Attorney—Paul B. Queally
24.10   *   Power of Attorney—David P. Zarin, M.D.
24.11   *   Power of Attorney—John C. Garrett, M.D.
24.12   *   Power of Attorney—Jerry P. Widman
24.13   *   Power of Attorney—Joel T. Allison
99.1   *   Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350
99.2   *   Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350

*
Filed herewith.

#
Previously filed.


(b)    Reports on Form 8-K

        The Company filed a report on Form 8-K dated October 3, 2002 to furnish, pursuant to Regulation FD, a schedule summarizing the Company's domestic same-facility case growth for the first three quarters of 2002.

        The Company filed a report on Form 8-K dated October 15, 2002 to furnish, pursuant to Regulation FD, a news release describing the Company's acquisition of a majority ownership interest in an ambulatory surgery center in northern Ohio and a minority ownership interest in an ambulatory surgery center in Fort Worth, Texas.

II-3



        The Company filed a report on Form 8-K dated October 30, 2002 to furnish, pursuant to Regulation FD, a news release describing the Company's third quarter results.

        The Company filed a report on Form 8-K dated November 12, 2002 to furnish, pursuant to Regulation FD, a copy of materials dated November 2002 and prepared with respect to presentations to investors and others that may be made by senior officers of the Company.

II-4




SIGNATURES

        Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    UNITED SURGICAL PARTNERS INTERNATIONAL, INC.

Date: March 25, 2003

 

By:

 

/s/  
DONALD E. STEEN      
Donald E. Steen
Chief Executive Officer and
Chairman of the Board

        Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in capacities and on the dates indicated.

Signature
  Title
  Date

 

 

 

 

 
/s/  DONALD E. STEEN      
Donald E. Steen
  Chairman of the Board and Chief Executive Officer (Principal Executive Officer)   March 25, 2003

/s/  
WILLIAM H. WILCOX      
William H. Wilcox

 

President and Director

 

March 25, 2003

/s/  
MARK A. KOPSER      
Mark A. Kopser

 

Senior Vice President and Chief Financial Officer (Principal Financial Officer)

 

March 25, 2003

/s/  
JOHN J. WELLIK      
John J. Wellik

 

Senior Vice President, Chief Accounting Officer, Compliance Officer and Secretary (Principal Accounting Officer)

 

March 25, 2003

*

James C. Crews

 

Director

 

March 25, 2003

*

D. Scott Mackesy

 

Director

 

March 25, 2003

 

 

 

 

 

II-5



*

Thomas L. Mills

 

Director

 

March 25, 2003

*

Boone Powell, Jr.

 

Director

 

March 25, 2003

*

Paul B. Queally

 

Director

 

March 25, 2003

*

David P. Zarin, M.D.

 

Director

 

March 25, 2003

*

John C. Garrett, M.D.

 

Director

 

March 25, 2003

*

Jerry P. Widman

 

Director

 

March 25, 2003

*

Joel T. Allison

 

Director

 

March 25, 2003

        John J. Wellik, by signing his name hereto, does hereby sign this Annual Report on Form 10-K on behalf of each of the above-named directors and officers of the Company on the date indicated below, pursuant to powers of attorney executed by each of such directors and officers and contemporaneously filed herewith with the Commission.


By:

 

/s/  
JOHN J. WELLIK      
Attorney-in-fact

 

March 25, 2003

II-6



CERTIFICATION

I, Donald E. Steen, Chairman of the Board and Chief Executive Officer of United Surgical Partners International, Inc. (the "Company"), certify that:


Date: March 25, 2003

/s/ Donald E. Steen

Donald E. Steen
Chairman of the Board and Chief Executive Officer
(Principal Executive Officer)

II-7



CERTIFICATION

I, Mark A. Kopser, Senior Vice President and Chief Financial Officer of United Surgical Partners International, Inc. (the "Company"), certify that:


Date: March 25, 2003

/s/ Mark A. Kopser

Mark A. Kopser
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)

II-8



INDEX TO EXHIBITS

Exhibit
Number

   
  Description
  2.1   #   Agreement and Plan of Merger, dated as of December 6, 2000, among the Company, OPC Acquisition Corporation and OrthoLink Physicians Corporation (previously filed as Exhibit 2.1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  2.2   #   Agreement for the Sale and Purchase of Shares and Loan Notes in Aspen Healthcare Holdings Limited, dated April 6, 2000, between Electra Private Equity Partners 1995 and others and Global Healthcare Partners Limited (previously filed as Exhibit 2.2 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  2.3   #   Agreement and Plan of Reorganization, dated as of March 26, 2002, by and among the Company, USP Acquisition Corporation, Surgicoe Corporation and each of the shareholders of Surgicoe named in the agreement (previously filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Commission on April 16, 2002 and incorporated herein by reference)
  3.1   #   Second Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to Amendment No. 4 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  3.2   #   Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the Company's Registration Statement on Form S-3 (No. 333-99309) and incorporated herein by reference)
  4.1   #   Form of Common Stock Certificate (previously filed as Exhibit 4.1 to Amendment No. 4 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.2   #   Indenture, dated as of December 19, 2001, among United Surgical Partners Holdings, Inc., the guarantor parties thereto and U.S. Trust Company of Texas, N.A. (previously filed as Exhibit 4.2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and incorporated herein by reference)
  4.3   #   Global Security, dated as of December 19, 2001, governing United Surgical Partners Holdings, Inc.'s outstanding 10% Senior Subordinated Notes due 2011 (previously filed as Exhibit 4.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2001 and incorporated herein by reference)
  4.4   #   Third Amended and Restated Stockholders' Agreement, dated March 27, 2000, by and among the Company and the security holders named therein (previously filed as Exhibit 4.2 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.1   #   Amended and Restated Registration Rights Agreement, dated April 30, 1998, by and among the Company and the security holders named therein (the "Registration Rights Agreement") (previously filed as Exhibit 4.3.1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.2   #   Amendment No. 1 to the Registration Rights Agreement, dated as of June 26, 1998, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.2 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.3   #   Amendment No. 2 to the Registration Rights Agreement, dated as of July 31, 1998, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.3 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.4   #   Amendment No. 3 to the Registration Rights Agreement, dated as of October 26, 1998, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.4 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)

  4.5.5   #   Amendment No. 4 to the Registration Rights Agreement, dated as of December 22, 1998, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.5 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.6   #   Amendment No. 5 to the Registration Rights Agreement, dated as of June 1, 1999, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.6 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.7   #   Amendment No. 6 to the Registration Rights Agreement, dated as of March 27, 2000, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.7 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.5.8   #   Amendment No. 7 to the Registration Rights Agreement, dated as of February 12, 2001, by and among the Company and the security holders named therein (previously filed as Exhibit 4.3.8 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
  4.6   #   Rights Agreement between the Company and First Union National Bank as Rights Agent dated June 13, 2001 (previously filed as Exhibit 4.1 to the Company's Form 8-A filed with the Commission on June 13, 2001 and incorporated herein by reference)
10.1   #   Credit Agreement, dated April 6, 2000, by and among Global Healthcare Partners Limited and the Governor and Company of the Bank of Scotland (previously filed as Exhibit 10.3 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.2   #   Second Amended and Restated Credit Agreement, dated as of November 7, 2002, among USP Domestic Holdings, Inc., USPE Holdings Limited, various financial institutions from time to time parties thereto as the lenders and Sun Trust Bank, as Administrative Agent (previously filed as Exhibit 10.1 to the Company's Annual Report on Form 10-Q for the quarter ended September 30, 2002 and incorporated herein by reference)
10.3   #   Contribution and Purchase Agreement, dated as of May 11, 1999, by and among USP North Texas, Inc., Baylor Health Services, Texas Health Ventures Group LLC and THVG/Health First L.L.C. (previously filed as Exhibit 10.11 to Amendment No. 2 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.4   #   Common Stock Purchase Warrant, dated June 1, 1999 (previously filed as Exhibit 10.15 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.5   #   Stock Purchase Warrant, dated March 27, 2000 (previously filed as Exhibit 10.16 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.6   *   Employment Agreement, dated as of November 15, 2002, by and between the Company and Donald E. Steen
10.7   *   Employment Agreement, dated as of November 15, 2002, by and between the Company and William H. Wilcox
10.8   #   Stock Option and Restricted Stock Purchase Plan (previously filed as Exhibit 10.19 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.9   #   2001 Equity-Based Compensation Plan (previously filed as Exhibit 10.20 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
10.10   #   Employee Stock Purchase Plan (previously filed as Exhibit 10.21 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)

10.11   #   Deferred Compensation Plan, effective as of February 12, 2002 (previously filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2002 and incorporated herein by reference)
10.12   #   Supplemental Retirement Plan, effective as of February 12, 2002 (previously filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2002 and incorporated herein by reference)
10.13   #   Form of Indemnification Agreement between the Company and its directors and officers (previously filed as Exhibit 10.22 to Amendment No. 1 to the Company's Registration Statement on Form S-1 (No. 333-55442) and incorporated herein by reference)
21.1   *   List of the Company's subsidiaries.
23.1   *   Consent of KPMG LLP for United Surgical Partners International, Inc.
24.1   *   Power of Attorney—Donald E. Steen
24.2   *   Power of Attorney—William H. Wilcox
24.3   *   Power of Attorney—Mark A. Kopser
24.4   *   Power of Attorney—John J. Wellik
24.5   *   Power of Attorney—James C. Crews
24.6   *   Power of Attorney—D. Scott Mackesy
24.7   *   Power of Attorney—Thomas L. Mills
24.8   *   Power of Attorney—Boone Powell, Jr.
24.9   *   Power of Attorney—Paul B. Queally
24.10   *   Power of Attorney—David P. Zarin, M.D.
24.11   *   Power of Attorney—John C. Garrett, M.D.
24.12   *   Power of Attorney—Jerry P. Widman
24.13   *   Power of Attorney—Joel T. Allison
99.1   *   Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350
99.2   *   Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350

*
Filed herewith.

#
Previously filed.